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MicroRNAs in normal and malignant lymphocytes 
Abstract 
MicroRNAs (miRNAs) are 20-22 nucleotide non-coding RNAs that can play important 
roles in developmental transitions by post-transcriptional regulation of mRNA translation and 
stability. We profiled miRNA expression in mouse thymocytes, mature T cells, and activated T 
cells, and identified distinctive patterns of miRNA expression during development, maturation, 
and activation of T cells. The miR-128 and miR-181 miRNA families are expressed at 
significantly higher levels in thymocytes. Examining the expression levels of these microRNAs in 
more detail, we observed that the expression pattern of these microRNA families distinguishes 
cells committed to lymphoid lineages from cells committed to myeloid lineages during normal 
mouse hematopoiesis. Extending this work to human malignancies, we determine that high miR-
128 expression distinguishes lymphoid precursor derived malignancies from myeloid precursor 
derived malignancies.   
Little information is available regarding miRNA expression early after CD8 T cell 
activation. We demonstrate dynamic miRNA expression during early CD8 T cell activation, 
including the repression of miR-150, miR-181a, miR-26, miR-29 and miR-30, and the induction 
of miR-155, miR-31, miR-146, and the miR-17-92 cluster. We show that miR-31 is induced by 
calcium/Calcineurin signaling during acute CD8 T cell activation, and demonstrate elevated miR-
31 expression in regulatory and memory T cell populations. We identify miR-31 targets in 
primary CD8 T cells and propose a model where miR-31 induction primes CD8 T cells for 
activation by promoting T cell survival, activation, and proliferation.  
Activation induced miRNA expression patterns are also found in some human 
malignancies. Chronic lymphocytic leukemia is typically thought to be a disease of resting 
lymphocytes. However, we demonstrate an activated B cell miRNA expression signature in CLL. 
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Similarities in miRNA expression between activated B cells and CLL cells include high 
expression of miR-34a, miR-155, and miR-342-3p and low expression of miR-103, miR-181a 
and miR-181b. Additionally, we show that decreased levels of miR-29c and miR-223 in CLL are 
negative prognostic markers associated with shorter time to first therapy. These data indicate an 
activated B cell status for CLL cells and suggest that the expression level of individual miRNAs 
may predict clinical course in CLL. 
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MicroRNAs (miRNAs) are small non-coding RNAs that post-transcriptionally regulate 
gene expression by annealing to complementary regions within mRNAs. The first miRNA (lin-4) 
was discovered by classical genetic screening in C. elegans [1, 2]. More recent research has found 
that miRNAs comprise a large and conserved class of regulatory RNAs in phyla as diverse as 
plants, arthropods, and chordates [3-5]. miRNAs have been shown to play critical roles in the 
hematopoietic system, where miRNA activity is important in shaping lineage choice, supporting 
differentiation, and modulating the immune response.  
miRNA transcription and post-transcriptional processing  
More than 700 miRNAs have been identified in the mouse genome [6]. The majority of 
these miRNA genes resemble protein-coding genes in that they are transcribed by RNA 
polymerase II as capped, polyadenylated, and sometimes spliced 100-1,000 nucleotide (nt)-long 
primary miRNA transcripts (pri-miRNAs) containing one or several miRNA stem loops [7, 8]. 
One major distinction between protein-coding genes and miRNAs is that the mature miRNA can 
be located within either an exon or an intron of the transcript. This provides the potential for a 
single transcript to code for both a protein and a miRNA, and the majority of mammalian 
miRNAs are found within introns of protein-coding genes [9, 10]. These miRNAs are thought to 
be co-transcribed with their host gene, although a few intronic miRNAs such as miR-21 can be 
transcribed from an independent promoter [11, 12]. Additionally, a rare subset of miRNAs is 
transcribed by RNA polymerase III [10] . 
The pri-miRNA transcript is processed in the nucleus by the Microprocessor complex 
minimally composed of the RNase III enzyme Drosha and the RNA binding protein DGCR8. 
This complex binds to and cleaves the miRNA hairpin, producing a ~70 nt precursor miRNA 
(pre-miRNA) [13]. The pre-miRNA is exported through the nuclear membrane by Exportin-5 and 
Ran-GTP [14, 15].  Some intronic miRNAs, known as mirtrons, bypass Drosha/DCGR8 
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processing and are produced directly as pre-miRNAs by splicing and debranching enzymes [16]. 
Once in the cytoplasm, the pre-miRNA loop is removed by another RNase III enzyme Dicer that 
cuts 21-23 nt from the base of the pre-miRNA, leaving a 21-23 nt staggered miRNA duplex.  One 
strand of this duplex (the miRNA strand) is then incorporated into the Argonaute (Ago) protein 
which forms the core of the RNA-induced silencing complex (RISC), while the complementary 
strand (the miRNA* strand) is degraded. While it is possible for either strand of the duplex to be 
incorporated into RISC, most miRNAs display a significant strand incorporation bias, with the 
miRNA strand predominating in RISC and its complementary miRNA* strand found at 
significantly lower levels in RISC [17].  
miRNA dependent gene silencing 
The mature miRNA mediates the sequence-specific binding of RISC to mRNAs 
complementary to the miRNA. Full complementarity leads to mRNA cleavage. However, this has 
been shown to occur only for one animal miRNA-mRNA pair [18]. Instead, almost all 
mammalian miRNA-mRNA pairings involve partial complementarity between the miRNA and 
sites in the 3’untranslated region (3’UTR) of its mRNA targets. Most important to this mode of 
binding is the 8 nt “seed” region at the 5’ end of the miRNA, with 3’ complementarity being of 
secondary importance [19]. Because of the importance of the seed region to binding, miRNAs are 
grouped into families with shared seed sequences, and members of these families are predicted to 
regulate overlapping sets of genes. Computational methods predict that more than half of all 
protein-coding genes may be regulated by miRNAs, suggesting that miRNAs play an important 
and poorly understood role in gene regulation [20, 21].  
miRNA-mediated RISC binding represses target mRNA expression through at least two 
mechanisms: translational inhibition and/or mRNA destabilization. Translational inhibition by 
miRNAs appears to act at the level of translational initiation, either by RISC competing with the 
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EIF4E initiation factor for the m
7
G cap binding, or by inhibiting joining of the 60S ribosomal 
subunit to the 40S ribosomal subunit [22, 23]. Transcript destabilization may involve selective 
recruitment of deadenylases by the GW182/TNRC6 component of RISC, followed by decapping 
and mRNA degradation in processing bodies (P-bodies) [24, 25].  
miRNAs in hematopoietic development 
The first miRNA was discovered in C. Elegans among the set of heterochronic genes, 
which drive cells to differentiate into the appropriate cell types for each developmental stage [1]. 
miRNA function is also essential for mammalian development, as loss of the Dicer or Drosha 
biosynthetic enzymes results in an embryonic lethal phenotype [26, 27]. Knockout embryos fail 
to form a body plan during gastrulation, and it has been impossible to isolate viable Dicer 
knockout embryonic stem cell (ES) lines [28].   
Hematopoiesis is a well-studied model of mammalian development. A small number of 
self-renewing multipotent hematopoietic stem cells (HSC) produce multiple mature cells to carry 
out the many functions of the hematopoietic system. Tight regulation of gene expression is 
essential to hematopoiesis, with well-known roles for the coordinated, stage specific expression 
of a network of transcription factors [29]. However, recent research has found that post 
transcriptional regulation by miRNAs also plays an important role in lineage specification and 
hematopoietic development. The essential role of miRNAs in the hematopoietic system has been 
demonstrated with conditional knockouts of Dicer in immune lineages. Dicer knockout in B cell 
progenitors results in a nearly complete block in development in the pro-B to pre-B transition, 
which could be partially reversed by the ablation of a single miRNA target [30].  Dicer knockout 
early in the T cell lineage does not lead to a developmental block, although T cell development is 
significantly impaired [31]. Peripheral T cells are more strongly affected by Dicer deletion, with 
defects in maturation, homeostatic proliferation, and antigenic response [32]. 
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Specific miRNAs have been identified which function during hematopoiesis to support 
HSC, or promote development of specific lineages, such as miR-125b and miR-451. miR-125b is 
highly expressed in HSC, and is expressed at progressively lower levels in more differentiated 
subsets. Ectopic expression of miR-125b increased HSC engraftment and output [33, 34]. miR-
125b represses pro-apoptotic proteins, such as Bmf and Klf13, and it is likely that repression of 
these proteins is partially responsible for the increase in HSC survival during engraftment and 
subsequent output. In contrast, miR-451 acts to promote terminal differentiation of the 
erythroblast hematopoietic lineage, thus regulating red blood cell production. miR-451 expression 
is strongly induced in erythroid tissues by the transcription factor GATA-1, and knockout of miR-
451 in mice impairs complete maturation of erythrocytes, leading to erythroid hyperplasia, 
splenomegaly, and anemia [35]. 
Individual miRNAs have also been shown to promote or block differentiation into 
lymphoid lineages. Chen et al. published the first study linking miRNA expression to lineage 
differentiation [36]. Chen et al. observed high expression of miR-181a in bone marrow and 
thymus, and found that ectopic expression of miR-181a in HSC resulted in an increase in B 
lineage cells in vivo. A second miRNA that plays an important role in hematopoiesis is miR-150, 
which is selectively expressed in mature T cells and B cells. [37]. miR-150 targets c-Myb, an 
important transcription factor expressed in developing but not mature B lineage cells [38]. 
Ectopic expression of miR-150 in developing B cells blocks differentiation at the ProB to PreB 
transition, whereas miR-150 deletion leads to elevated levels of B1 B lineage cells [38]. 
miRNAs in the immune response 
In addition to their regulation of hematopoietic development, miRNAs also play 
important roles during the immune response. Careful control of the immune response is required 
to maximize anti-pathogen activity while preventing excessive and deleterious immune reactions. 
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miR-146a and miR-155 are selectively expressed in activated cells of the immune system. [39-
43], and studies utilizing knockout mice have revealed that miR-155 and miR-146a play essential 
roles in tuning the immune response to pathogens.   
Research into the immunological role of miR-155 was greatly advanced by the 
production of miR-155 knockout mice by two independent groups, Rodriguez et al. and Thai et 
al. [44, 45].  Consistent with the observed miR-155 expression pattern, both groups observed 
normal hematopoietic development followed by serious defects in immune function. B cells from 
miR-155 knockout mice secreted lower levels of IgM and reduced class switched antibodies after 
immunization, a phenotype associated with defective germinal center formation.  Thai et al. 
attribute the changes in GC formation to deficiencies in the production of the GC-promoting 
chemokines lymphotoxin-and tumor necrosis factor by miR-155 knockout B cells. miR-155 
knockout CD4 T cells displayed a pronounced bias towards secretion of Th2 type cytokines, 
which Rodriguez et al. link to the deregulation of the miR-155 target c-Maf, a Th2 specific 
transcription factor [46] . The defects in immune function in miR-155 mice prevented them from 
mounting a protective immune response to bacterial vaccinations. In addition, Rodriguez et al. 
also observed autoimmune phenotypes in the lungs of miR-155 knockout mice. More recent 
research has found that miR-155 is induced in regulatory T cells (Treg) by the Foxp3 
transcription factor, and promoted Treg development [47]. These results show that miR-155 plays 
important roles in initiating an effective adaptive immune response and in preventing 
autoimmunity.  
miR-146a is induced in myeloid cells after stimulation with Toll like receptor (TLR) 
ligands or pro-inflammatory cytokines such as tumor necrosis factor alpha (TNF-[48]. miR-
146a is also upregulated during the early activation of CD4 T cells, and displays biased 
expression in differentiated CD4 Th1 T cells [37, 49]. miR-146a knockout mice produced by 
Boldin et al. exhibit hyper-inflammatory responses to TLR stimulation characterized by 
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production of excessive amounts of pro-inflammatory cytokines [50]. In addition, aged miR-146a 
knockout mice develop an autoimmune condition involving splenomegaly, T cell activation, and 
autoantibody production. Release of pro-inflammatory signaling molecules including Irak1, 
Irak2, and Traf6 from miR-146a repression contributes to this hyper-inflammatory phenotype 
[51]. These results indicate that miR-146a expression in activated T cells and myeloid cells drives 
a negative feedback loop which attenuates the immune response and prevents excessive 
inflammation.  
miRNAs in hematopoietic malignancies 
The importance of miRNAs to the hematopoietic system has been emphasized by the 
links between miRNAs and hematopoietic malignancies. Many miRNAs display similar 
expression between cancers and their originating cell type. This miRNA fingerprint links cancers 
to normal cell types and provides clues to malignant ontogeny [52]. However, some miRNAs 
have cancer specific expression. Cancer specific miRNA expression can serve as a prognostic 
marker, and a subset of miRNAs have been shown to directly function as oncogenes or tumor 
suppressors  [53].  miRNA loci are often located in genomic regions that are deleted or amplified 
in cancers, including those of hematopoietic origin [54]. One example was published for chronic 
lymphocytic leukemia (CLL), where Calin et al. reported that two miRNA genes, miR-15a and 
miR-16-1, were located at a chromosomal region frequently deleted in CLL [55]. miR-15a and 
miR-16 repress Bcl-2, and de-repression of this anti-apoptotic gene is linked to defective 
apoptosis observed in CLL [56]. The first demonstrated oncogenic miRNA was miR-155, 
encoded by the BIC locus. Ectopic expression of miR-155 was shown to synergize with Myc to 
drive erythroleukemogenesis and lymphomagenesis in chickens [57]. Expression of miR-155 
alone in mouse B cells is sufficient to drive aberrant cellular proliferation and development of 
leukemia and lymphoma in mice [58]. miR-155 targets in hematological malignancies include 
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Smad5 and Ship1[59, 60]. miR-155 expression is a signature of many cancers of hematopoietic 
and non-hematopoietic origin, indicating the potent oncogenic potential of this miRNA (reviewed 
in [61]).  
miRNAs clearly play an important role in regulating cellular differentiation, with many 
of the most definitive demonstrations of this role found in the hematopoietic system. Further 
studies on miRNA expression and function during hematopoiesis will serve to unravel the 
complicated network of gene regulation which underlies differentiation and lineage choice, as 
well as providing a deeper understanding of miRNA function. miRNA knockout data indicates 
that the adaptive T cell response is tuned and regulated by selective miRNA expression. 
However, most published studies have focused on the role of miRNAs in CD4 T cells, with 
relatively little known regarding the role of miRNAs in CD8 T cells. Investigation of miRNA 
expression and activity in the CD8 T cell compartment will improve our understanding of the role 
of miRNA regulation of the cytotoxic T cell response.  
Comparison of miRNA expression in normal and malignant hematopoietic tissues can 
provide insight into oncogenesis. First, miRNA profiles link tumors to their cell type of origin. 
Second, miRNA expression patterns can be associated with prognosis, and can thus provide 
useful clinical information.  Third, loss and gain of miRNA expression can drive oncogenesis, 
raising the possibility of miRNA based therapeutics.  
  













miR-128 and miR-181 family members are selectively induced in lymphoid  
lineages during hematopoiesis 
 




MicroRNAs (miRNAs) are 20-22 nucleotide non-coding RNAs that can play important 
roles in developmental transitions by post-transcriptional regulation of mRNA translation and 
stability. We profiled miRNA expression in mouse thymocytes, mature T cells and activated T 
cells and identified miRNAs selectively expressed in developing thymocytes, the majority of 
which derived from the miR-128 and miR-181 miRNA families. Examining the expression levels 
of these miRNAs in more detail, we observed that the expression pattern of these miRNA 
families distinguishes cells committed to the lymphoid lineages from cells committed to myeloid 
lineages in both normal mouse hematopoiesis and in human hematopoietic malignancies.  




Hematopoiesis proceeds through the production of multiple mature cell types from self-
renewing multipotent hematopoietic stem cells (HSC), a process that involves the tight regulation 
of large networks of genes. Regulation of transcription by classical transcription factors is 
essential to this process [29]. However, recent research has found that post-transcriptional 
regulation by microRNAs (miRNAs) also plays an important role in lineage specification and 
hematopoietic development.  
Mature hematopoietic cells are derived from the progressive restriction of cell fate in 
increasingly specialized progenitor cells. One of the earliest identified lineage restrictions occurs 
in the progenitor cells that give rise to lymphoid and myeloid cells, the two major lineages of 
hematopoietic cells. The common lymphocyte progenitor (CLP) can give rise to all lymphoid 
lineages, including T, B, and natural killer (NK) cells but has limited myeloid developmental 
potential [62, 63]. In contrast, the common myeloid progenitor (CMP) can give rise to all the 
myeloid cell types, but not to lymphoid cells [64]. Downstream of the common myeloid 
progenitor are two increasingly specialized myeloid lineage progenitors: the 
megakaryocyte/erythrocyte progenitors (MEP), which differentiate into platelets and red blood 
cells, and the granulocyte monocyte progenitors (GMP), which give rise to the remaining myeloid 
cell types including macrophages, mast cells, granulocytes, and monocytes [65]. After 
commitment to the lymphoid lineage, cells develop into T cells and B cells in the thymus and 
bone marrow through distinct stages which correspond to the progressive rearrangement of the T 
cell receptor (TCR) and B cell receptor (BCR) loci and selection of the antigen repertoire.  
Strong evidence for the essential roles of miRNAs in hematopoiesis comes from 
conditional deletion of the key miRNA biogenesis enzyme Dicer. Loss of Dicer in HSCs results 
in a loss of the long-term repopulating stem cell pool in vivo [66]. Loss of Dicer in B or T cell 
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precursors results in significant developmental blocks and aberrant differentiation of mature cells 
[30, 67]. In addition, specific miRNAs have been shown to regulate the development of 
individual hematopoietic lineages (reviewed in [68]). There is substantial overlap between factors 
which regulate normal hematopoiesis and those which are dysregulated in hematological cancers. 
Thus, tracking expression of miRNAs during normal and malignant hematopoiesis may yield 
important insights into the shared and divergent roles that miRNA regulation plays in 
hematopoiesis and leukemogenesis. 
In the current investigation, we produced a detailed profile of miRNAs expressed during 
T cell development. We identified two families of miRNAs, miR-128 and miR-181, which are 
selectively expressed in developing T cells. Examining the expression of these two families in 
cells from other hematopoietic lineages, we found that the expression of these two miRNAs 
distinguish lymphoid lineages from myeloid lineage cells in both normal murine hematopoiesis 
and lymphoid malignancies.    
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Materials and Methods 
Mice 
Male c57bl/6 mice between 5-10 weeks of age were purchased from Taconic Farms 
(Hudson, NY, USA). 
Patient samples and cell preparation 
Samples were obtained from patients and normal donors enrolled on clinical research 
protocols at the Dana-Farber Cancer Institute approved by the DFCI Human Subjects Protection 
Committee. Peripheral blood mononuclear cells were isolated by Ficoll/Hypaque density gradient 
centrifugation, cryopreserved with 10% DMSO, and stored in vapor-phase liquid nitrogen until 
the time of analysis. CD34+ cells from normal donor bone marrow aspirate were isolated by 
means of a fluorescence-activated cell sorter. 
Total RNA preparation 
Total RNA was extracted by the Trizol method (Invitrogen, Carlsbad, CA, USA). Dried 
RNA pellets were re-suspended in appropriate volumes of nuclease-free water. RNA was 
quantitated by O.D.260/280 using a spectrophotometre DU640 (Beckman). 
miRNA expression profiling 
We profiled 279 miRNAs by the Luminex method as described elsewhere [52]. Profiling 
data was normalized by generating a mean array for the expression of each miRNA in all 
samples. Next, a linear correction for each sample to the mock array was performed. Hierarchical 
clustering was performed using GenePattern software from the Broad Institute [69]. 
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miRNA-specific RT-PCR assay 
miRNA specific cDNA synthesis from total RNA was carried out using MicroRNA 
Reverse Transcription Kit (Applied Biosystems, Carlsbad, CA, USA). miRNA-specific RT-PCRs 
were performed using Taqman miRNA assays according to the manufacturer's protocol (Applied 
Biosystems, Carlsbad, CA, USA). miRNA expression was calculated using a standard curve 
derived from a matched synthetic single stranded miRNA. 
Fluorescence activated cell sorting for miRNA profiling: 
Samples of mouse HSC, CMP, GMP, and MEP were obtained from the laboratory of Dr. 
Akashi and isolated as previously described [62, 64, 65] 
For isolation of thymocytes, thymocytes were stained with-CD117, -CD44, -CD25, 
-CD8,  -CD4, and -CD24 antibodies. Cells were isolated as follows: early CD8 SP (CD8+ 
CD4- CD24high); late CD8 SP (CD8+ CD4- CD24low); DP (CD4+ CD8+); DN (CD4- CD8-). 
DN cells were further subdivided by expression of CD117, CD44, and CD25 as follows: DN1 
(CD117high CD44high CD25-); DN2 (CD117high CD44high CD25+); DN3 (CD117med 
CD44med CD25+) ; DN4 (CD117low CD44low CD25-). For isolation of mouse B cell 
progenitors, red blood cells were removed from mouse bone marrow with red blood cell lysing 
buffer (Sigma, St. Louis, MO, USA). Cells were stained with a panel of non-B lineage markers ( 
CD3,  -GR1,  -TER-119, -CD11B and -DX5), and -CD117,  -CD127,  - CD19 and  
-B220. Cells were isolated as follows: CLP (Lin- CD19- B220- CD117+ CD127+); ProB (Lin- 
CD19- B220+ CD117+ CD127+); PreB1 (Lin- CD19+ B220+ CD117+ CD127+); PreB2 (Lin- 
CD19+ B220+ CD117- CD127+). For isolation of mature T cells and B cells, red blood cells 
were removed from mouse bone marrow with red blood cell lysing buffer, and cells stained with 
-CD19, -B220, and -CD3. B cells were isolated as CD19+ B220+, and T cells as CD3+. All 
antibodies were obtained from eBioscience (San Diego, CA, USA) 
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Primary Cell Culture and Activation 
CD8 T cells were isolated from 5-10 week old c57Bl/6 mice by negative selection using 
EasySep beads (Stemcell Technologies, Vancouver, BC, Canada.). T cells were cultured in 
RPMI-1640 Medium supplemented with 10% fetal calf serum, 50 units/ml Penicillin-
Streptomycin, 10 mM HEPES, 2 mM L-glutamine, and 55 M 2-mercaptoethanol (GIBCO, 
Carlsbad, CA, USA). Cells were cultured at 37°C with 5% CO2. T cells were activated with 10 
μg/ml plate bound a-CD3 and 2 μg/ml soluble -CD28 antibodies (eBioscience, San Diego, 
CA, USA ), and RNA was isolated from cells 24 hours and 96 hours after activation.  
BM derived dendritic cells were generated as described [70]. For dendritic cell activation, 
cells were cultured in media containing lipopolysaccharide (LPS) (10 ng/ml Alexis, San Diego, 
CA, USA) for 24 hours prior to miRNA profiling.   
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Results and Discussion 
miRNA profiling during T cell ontogeny 
To identify miRNAs with developmental stage-specific expression during T cell 
ontogeny, we used a Luminex bead-based system to profile miRNA expression. Solution-phase 
Luminex detection can accurately distinguish between miRNAs with only a single mismatch, and 
offers linear detection over a hundred-fold range of expression [52]. We obtained miRNA profiles 
from thymocytes, mature T and B cells, activated CD8 T cells, bone marrow-derived dendritic 
cells (DC), and control kidney and liver tissue perfused to remove contaminating lymphocytes. 
Unsupervised hierarchical clustering of miRNA profiles classified samples from solid tissues, 
DCs, and B or T lineage cells into 3 separate groups (Figure 2.1A). Within the T lineage, distinct 
clusters of miRNAs are expressed in a developmental stage-specific manner. First, miRNAs 
which are selectively expressed in developing thymocytes in comparison to all other tissues tested 
(Figure 2.1B). Second, miRNAs which are selectively expressed after maturation of T and B cells 
(Figure 2.1C). Third, miRNAs which are induced by T cell activation, some of which are also 
expressed at high levels in bone marrow-derived DC or solid tissues (Figure 2.1D). Our miRNA 
profiles thus distinguish both lineage and T cell developmental stage.  
Interestingly, the majority of miRNAs selectively expressed in thymocytes come from 
just two families, miR-181 (a, b, and c) and miR-128. miR-181a, b, and c family members are 
present in 3 separate loci. miR-213, which is also present in this cluster, is the mir* partner for 
miR-181-a-1. miR-128 is present in the mouse genome at two loci. These two loci were initially 
thought to produce miR-128a and miR-128b, miRNAs with a 1 nt difference at the 3’-end. 
However, deep sequence data indicates that the most commonly produced mature miRNAs from 
these two loci are identical, so they have been renamed miR-128-1 and -2 [71]. The coordinated 
induction of multiple family members from separate loci suggests that expression of miR-128 and  
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Figure 2.1: Luminex profiles of miRNA expression in T lineage and control tissues. A: 
Pairwise complete linkage hierarchical clustering of all miRNAs expressed at >3 standard 
deviations over background in at least one sample. Samples include total thymocytes, DP 
thymocytes, mature T cells and B cells, 24 hour and 96 hour  -CD3/CD28 activated CD8 T 
cells, bone marrow-derived DC, lipopolysaccharide (LPS) activated DCs, and control kidney and 
liver tissue perfused to remove contaminating lymphocytes. Data represents expression relative to 
the mean value for each row. Groups of miRs are differentially expressed in developing (B), 
mature (C), and activated T cells (D).  
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miR-181 family members may be a distinctive feature of T cell development. 
Real-time PCR validates miR-128 and miR-181 expression during T and B cell 
development  
To independently validate the expression of miR-128 and miR-181 family members, we 
examined the expression of these miRNAs during T cell development in more detail by real time 
PCR (RT-PCR) [72]. RT-PCR can operate efficiently with limited biomass, allowing us to profile 
the expression of miR-128 and miR-181 in low-frequency populations, including individual 
thymocyte subsets.  
Thymocyte development proceeds through multiple stages, which can be distinguished 
by the expression of surface markers (Figure 2.2A). Cells in the earliest stage of T cell 
development lack CD4 and CD8 surface expression, and are known as double negative cells 
(DN). DN can be further subdivided into 4 subsets by the expression of CD25, CD44, and CD117 
(c-kit) (Figure 2A). Inclusion of the CD117 marker is essential for the isolation of DN1 and DN2 
T-lineage cells since (a) expression of the CD44 marker is common among non-T lineage cells 
and (b) the majority of the T cell developmental potential present within the DN1 stage is 
restricted to the small population of cells which also express high levels of CD117 [73]. During 
the double negative stage, cells lose the ability to commit to non-T lineages (DN1-2), and 
rearrange the TCR- locus (DN2-3) [74]. Next follows the double positive stage (DP), in which 
cells express both CD4 and CD8, and undergo TCR- rearrangement. Starting at the DP stage, 
thymocytes go through a process of positive selection, which enables survival of thymocytes 
which have successfully rearranged a TCR with the capability to bind to major histocompatibility 
complex (MHC) molecules, and negative selection, which eliminates thymocytes with high 
affinity for self antigens that could pose a risk of autoimmunity[75]. Single positive cells (SP) 
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express either CD4 or CD8, and continue to go through negative selection as they complete 
maturation in the thymus, which corresponds to a decline in CD24 expression [76, 77]. 
We purified thymocyte populations by FACS according to surface marker expression and 
tested their miRNA expression. RT-PCR results found high expression of both miR-128 and 
miR-181 family members, confirming our Luminex profile data. However, comparison of 
thymocyte subsets revealed distinct changes in miRNA expression over the course of T cell 
development. High expression of both miR-128 and miR-181 family members was observed at 
the earliest DN1 stage of T cell development. Expression dipped at the DN2 stage, recovered at 
DN3, and then progressively declined during subsequent thymocyte development, with the 
expression of miR-128, miR-181b and miR-181c lost as single positive cells matured and left the 
thymus. miR-181a expression was increased at the early single positive stage, and was the only 
signature miRNA to remain expressed in mature T cells, albeit at significantly lower levels 
(Figure 2.2B). These data confirm our Lumiex profiles, and reveal dynamic regulation of miRNA 
levels at individual stages of thymocyte development.  
Despite the known importance of miRNAs to T cell development, there are relatively few 
publications examining miRNA expression in detailed thymocyte populations. Nielson et al.  
profiled miRNA expression during thymocyte development by cloning and sequencing short 
RNAs [78]. Consistent with our results, these authors observed expression of miR-128 and miR-
181 family members in thymocyte subsets, with a peak in miR-128 expression at the DN4 stage, 
and a peak in miR-181a and b expression at the DP stage. Neilson et al. did not profile DN2 stage 
thymocytes, nor did they observe miR-128 or miR-181 family enrichment in the DN1 thymocyte 
stage [78]. Li et al. tracked miR-181a expression during thymocyte development, and reported 
peak expression at the DN3 stage, with lower expression in DN1 and DN2 [79]. Both of these 
groups defined the DN1 stage using the classical surface marker pattern of DN CD44+ CD25-. 
However, a large fraction of this population consists of non-T lineage cells which could interfere 
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with the detection of lineage-specific miRNA expression. By carefully isolating the CD117-high 
T-lineage progenitors from the bulk DN1 population, we were able to detect the distinctive 
expression of miR-128 and miR-181 family members in the earliest definitive T cell progenitor in 
the thymus.  
In order to determine if expression of miR-128 and miR-181 is T cell specific or a 
general feature of lymphoid development, we also profiled miRNA expression in the B cell 
lineage by RT-PCR. B cell development from the CLP in the bone marrow is highly analogous to 
T cell development, with subpopulations at distinct developmental stages bearing unique patterns 
of surface marker expression (Figure 2.2A). Pro-B cells are committed to the B lineage, Pro- and 
Pre-B1cells rearrange the immunoglobulin heavy locus , and Pre-B2 cells rearrange the  or  
light chain locus prior to the final stages of B cell maturation in the periphery [74]. We sorted 
CLP and developing B cell subtypes from bone marrow and tested miRNA expression by RT-
PCR. Strong expression of miR-128 and miR-181a and b was found in developing B cells at the 
Pro-B and Pre-B2 stage. Pre-B1 stage cells expressed lower but still detectable levels. Most 
notably, miR-128 and miR-181a and b expression was high in bone marrow CLP cells. These 
data indicate that miR-128 and miR-181 family expression is a feature of both developing B and 
T-lineage cells, and that induction of these miRNAs occurs before commitment to the T cell or B 
cell lineage.  
 The expression of miR-181 but not miR-128 has previously been reported in B cell 
development. miR-181a was one of the first miRNAs identified as being differentially expressed 
during hematopoiesis. Chen et al. demonstrated that miR-181 was overexpressed in mouse bone 
marrow and thymus [36]. Spierings et al. profiled miRNA expression by deep sequencing during 
mouse B cell development, and confirmed high expression of miR-181 in early B cell subsets 
[80]. Our experiments indicate that miR-128 is a marker of B cell development, and confirm 
previous research regarding the expression of miR-181 during B cell development. 
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Figure 2.2: miR-128 and miR-181 family members are expressed during both B and T cell 
development. A) Stepwise developmental stages during T cell development in the thymus and B 
cell development in the bone marrow, culminating in mature T and B cells in the periphery. B) 
miRNA expression in T-lineage populations of double negative (DN1-4), double positive (DP), 
early CD24+ CD8 single positive (early SP), late CD24- CD8 single positive (late SP) cells were 
isolated from the thymus, and mature T cells from the spleen. C) miRNA expression in CLP and 
B-lineage cells from the bone marrow and mature B cells from the spleen. MicroRNA levels were 
determined by real time PCR using a standard curve of synthetic RNA input to determine 
absolute expression. 
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Figure 2.2 (Continued) 
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miR-128 and miR-181 are markers for lymphoid commitment  
Since miR-181 and miR-128 families were expressed in the earliest T-lineage population 
in the thymus, the early B-lineage in the bone marrow, and in the bone marrow common 
lymphoid progenitor, we measured expression of these miRNA families earlier in hematopoietic 
development by RT-PCR to determine at what stage of development these miRNA families were 
induced. Both miR-128 and miR-181 family members are expressed at low but detectable levels 
in HSC. As commitment to the lymphoid lineage increases from HSC to CLP, and subsequently 
to early and late T-lineage committed cells (DN1 and DP), the expression of miR-181 and miR-
128 family members also increases. In contrast, during myeloid development, as HSC 
differentiate to the CMP, and the CMP further differentiates into the GMP and MEP, the 
expression of miR-128 and miR-181 family members decreases (Figure 2.3). These data indicate 
that expression of miR-128 and miR-181 family members is a general feature of commitment to a 
lymphoid rather than myeloid cell fate.  
A number of groups have profiled miRNA expression in HSC from mice and humans 
[33, 34]. However, there is limited information available on the expression of miRNAs in other 
committed hematopoietic progenitor populations. Georgantas et al. detected miR-128 and miR-
181 expression in human HSC, and based on computational miRNA-target predictions 
hypothesized that expression of miR-181 and miR-128 would prevent differentiation from HSC 
into both lymphoid and myeloid cell types [81]. We have demonstrated a progressive increase in 
miR-128 and miR-181 family expression during lymphoid lineage differentiation, therefore 
expression of these miRNAs cannot be associated with preserving a multipotent stem cell state, 
though they might act to inhibit myeloid differentiation.  





Figure 2.3: Expression of miR-128 and miR-181 families distinguishes developing lymphoid 
and myeloid lineages. Progenitor and mature populations were sorted from mouse spleen, 
thymus and bone marrow. miRNA expression in sorted progenitor and mature populations was 
determined by real-time PCR with a standard curve to calculate absolute expression. Populations 
are mature T cells, DP thymocytes, DN1 thymocyte T cell progenitors, CLP, HSC, CMP, GMP, 
and MEP. Row-normalized expression is shown.  
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Functional roles of miR-128 and miR-181 in normal hematopoiesis 
The functional role of miR-128 in hematopoiesis is unknown. However, publications 
regarding the tumor suppressive activity of miR-128 in human tumors offer some suggestions for 
the role miR-128 may play in hematopoiesis. One published target of miR-128 in human glioma 
is the Bmi-1 stem cell renewal factor, a member of the Polycomb group of genes [82]. Bmi-1 
expression plays an important role in hematopoietic stem cell renewal and in thymocyte 
proliferation in response to pre-TCR signaling [83, 84]. A second published target of miR-128 in 
acute lymphocytic leukemia is the mixed lineage leukemia gene, which is essential for the 
maintenance of adult HSC and myeloid/erythroid progenitors [85, 86]. These known targets, 
together with our expression data suggest that miR-128 may affect stem cell self-renewal, 
regulate the survival and proliferation of thymocytes, or repress myeloid differentiation.  
In contrast to miR-128, important regulatory roles for the miR-181 family have been 
identified at multiple stages of lymphoid lineage development. Expression of miR-181a in 
hematopoietic progenitors increases the production of lymphoid lineages appropriate to the 
developmental environment: ectopic expression of miR-181a in bone marrow promotes B cell 
development, and ectopic expression of miR-181a in early thymic progenitors promotes 
development to the DP stage [36, 87]. The mechanism by which miR-181a affects early 
development into lymphoid lineages remains to be established. miR-181a also plays an important 
role in shaping the developing T cell repertoire and in regulating the activation of mature T cells. 
In this role, miR-181a acts to decrease the minimum threshold for TCR signaling by repressing a 
group of inhibitory phosphatases which target pathways downstream of TCR triggering [79, 88]. 
High expression of miR-181a during late thymocyte development partially explains the decreased 
threshold for TCR triggering during positive and negative selection. Other groups have identified 
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additional miR-181a targets in thymocytes, including Bcl-2, CD69, and TCRα, which may also 
play a role in modulating thymocyte selection [78]. 
miR-128 and miR-181 expression in hematopoietic malignancies  
Many leukemias exhibit the clonal expansion of cells which exhibit maturation defects at 
specific points in hematopietic differentiation. Acute myeloid leukemias (AML) are myeloid 
precursors blocked at a variety of stages in development, whereas acute lymphoblastic leukemias 
(ALL) occur in immature B or T cell precursors [89, 90]. In contrast, chronic myeloid leukemia 
(CML) is a HSC disorder driven by a chromosomal fusion which produces the bcr-Abl 
oncogene[91, 92]. CML disease progression is complex: the initial chronic phase of disease is 
characterized by the production of abnormal levels of normal mature non-lymphoid cells, and is 
followed by a late stage of disease known as the blast crisis, with some patients experiencing an 
intervening accelerated phase with increasingly abnormal leukocyte counts [93]. The blast crisis 
phase is characterized by the rapid expansion of a population of immature myeloid or lymphoid 
cells, with clinical and hematological features similar to acute leukemia [94]. Since these 
malignancies are shaped by aberrant differentiation into lymphoid or myeloid pathways, we 
hypothesized that the miRNA expression patterns we observed in normal murine hematopoiesis 
might be conserved in human hematopoietic malignancies.  
 We tested miRNA expression in RNA isolated from patients with AML, ALL, chronic 
CML, myeloid and lymphoid blast phase CML, and from normal donor CD34+ cells (Figure 2.4). 
miR-181a and b family members were expressed in both the lymphoid tumors and in some CML 
and AML patients. This is consistent with previous reports of elevated miR-181 expression in 
subsets of AML and CML. In AML, miR-181 expression is associated with less mature leukemic 
subtypes [95]. In CML, miR-181 expression is high during blast crisis but variable in samples 
from earlier disease stages [96]. miR-128 was expressed only in lymphoid tumors and normal  





Figure 2.4: Expression of miR-181 and miR-128 distinguishes lymphoid and myeloid lineage 
human tumors. MicroRNA expression in sorted normal donor CD34+ bone marrow (ND CD34+) 
and patient tumor samples from: chronic phase CML [CML-C], myeloid blast phase CML [CML-
MB], lymphoid blast phase CML [CML-LB], ALL, and AML was determined by real-time PCR. 
Row-normalized expression is shown.  
   
29 
 
donor CD34+ cells. These data corroborate results from other groups who found that miR-128 
was the most significantly over-expressed miRNA in ALL compared to AML [97]. In addition, 
our results indicate that expression of miR-128 is also a distinctive marker of aberrant 
differentiation into the lymphoid lineage in CML blast crisis. 
Conclusions 
We have demonstrated that developing lymphoid lineage cells express a distinct miRNA 
signature of miR-128 and miR-181 family members during murine hematopoiesis. These 
miRNAs are induced progressively as cells differentiate towards lymphoid cell fates, and 
expression is maintained through T cell development in the thymus and B cell development in the 
bone marrow. The connection between miRNA expression in the CLP and in the earliest T-
lineage cells in the thymus is a unique aspect of our signature. The expression of miR-128 is 
conserved as a signal of lymphoid lineage in human hematopoietic malignancies.  
The function of miR-181a in regulating TCR sensitivity late in T cell development has 
been well described. However, the mechanism by which miR-181 family members affect early T 
and B cell development remains to be established, and almost nothing is known about the 
function of miR-128. Further investigation into the role of miR-128 and the miR-181 family 
during normal and malignant hematopoiesis is required to understand what role miRNAs play in 
the intricate network of genes that regulate hematopoiesis.  
 
  













MicroRNA expression profiling identifies activated B cell status in chronic 









This chapter is adapted from a published work [98]. 




Chronic lymphocytic leukemia (CLL) is thought to be a disease of resting lymphocytes. 
However, recent data suggest that CLL cells may more closely resemble activated B cells. Using 
miRNA expression profiling of highly-enriched CLL cells from 38 patients, 9 untransformed B 
cells from normal donors before acute CpG activation, and 5 matched B cells after acute CpG 
activation, we demonstrate an activated B cell status for CLL. Gene set enrichment analysis 
(GSEA) identified statistically-significant similarities in miRNA expression between activated B 
cells and CLL cells including upregulation of miR-34a, miR-155, and miR-342-3p and 
downregulation of miR-103, miR-181a and miR-181b. Additionally, decreased levels of two CLL 
signature miRNAs, miR-29c and miR-223, are associated with ZAP70
+
 and IgVH unmutated 
status and with shorter time to first therapy. These data indicate an activated B cell status for CLL 
cells and suggest that the direction of change of individual miRNAs may predict clinical course in 
CLL. 




CLL is the most common form of adult leukemia in the western world, accounting for 
approximately 30% of all leukemias in Caucasians. Contrary to its earlier description as a 
relatively homogeneous disease, CLL has recently been viewed as a heterogeneous disease with 
variable clinical course that correlates with several biologic markers of prognosis [99]. The most 
clinically significant prognostic markers are cytogenetics, as determined by fluorescence in situ 
hybridization (FISH), and immunoglobulin heavy chain variable region (IgVH) mutation, 
followed by ZAP70 status.  Deletion of 11q or 17p, high expression of ZAP70
 
or CD38, and 
relative absence of V region somatic hypermutation are markers of more aggressive CLL disease. 
CLL is characterized as a disease of mature B cells. CLL cells typically express an 
anergic B cell receptor (BCR) and demonstrate dysregulated apoptotic programs. mRNA 
expression profiling has been used to classify CLL [100-103]. Though it is not generally 
considered a disease of activated B cells, mRNA expression profiling characterized CLL cells as 
similar to activated B cells in one study [100] and similar to memory B cells in another [101]. In 
normal B cells, the nuclear translocation of NF-B is associated with B cell activation. 
Constitutive nuclear localization of nuclear factor of activated T cells (NFAT) and NF-B2/p52 
characterizes CLL cells [104], suggesting an activated B cell state. Moreover, CLL cells 
demonstrate higher NF-B DNA binding activity than untransformed B cells, the RelA subunit of 
NF-B has been shown to be associated with clinical disease progression, and RelA binding 
activity is inversely correlated with apoptosis in CLL cells [105]. Recently, CLL cells were 
shown to express activated cell surface markers and intracellular phenotypes [106].  
CLL has also been classified by miRNA expression profiling [107-112]. These profiles 
found correlations between miRNA expression and known clinically significant prognostic 
markers, and raised the potential for miRNAs to serve as independent prognostic markers. In 
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addition to their utility as markers, downregulation of several miRNAs has been linked to the 
apoptotic defect observed in CLL. Downregulated miR-15a and miR-16 fail to repress Bcl-2 
[113] and downregulated miR-29 fails to repress Mcl-1 [114]. However, it is important to note 
that there is considerable variation in the published miRNA expression profiles for CLL, 
indicating a need for additional research in this area.  
Using miRNA expression profiling, we identified a miRNA signature in untransformed B 
cells induced soon after activation. This activated B cell miRNA signature is also present in CLL 
cells indicating an activated B cell phenotype for CLL. Our data imply that individual miRNAs 
involved in B cell activation may participate in the B cell transformation process and could be 
targets for therapeutic gene silencing in CLL. 
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Materials and Methods 
Control B cell donor and CLL cell patient characteristics 
Cells from 38 CLL patients were assessed in this study. All patients were enrolled on a 
tissue banking protocol, #99-224, prior to sample collection. This tissue banking protocol was 
approved by the Dana-Farber Cancer Institute (DFCI) Institutional Review Board, and informed 
consent was obtained from all CLL patients prior to sample collection. These patients had white 




 cells per microliter of blood. Three of 
the CLL patients were treated, while the other 35 patients were untreated. Control blood samples 
were from healthy donors. ZAP-70 was assessed by flow cytometry, and the expressed IgVH was 
determined by reverse transcription polymerase chain reaction (RT-PCR) and enzyme-linked 
immunosorbent assay as previously described [115]. ZAP-70 expression (positive defined as 
>20%) and IgVH homology (unmutated defined as greater than or equal to 98% homology to the 
closest germline match) were determined by the CLL Research Consortium tissue core. Full 
patient clinical parameters are published in Li et al [98]. 
Control B cell and CLL cell purification 
10 mL of heparinized peripheral blood was subjected to Ficoll-Paque
TM 
PLUS (GE 
Healthcare, Pittsburgh, PA, USA) density centrifugation. Control B and CLL cells were purified 
from peripheral blood mononuclear cells (PBMCs) by positive selection with CD19+ selection 
beads as suggested by the manufacturer (StemCell Technologies Inc, Vancouver, Canada), and 
then immediately used for RNA isolation or activation treatment. 
Control B cell culture and activation 
B cells were cultured in Iscove's Modified Dulbecco's Medium (IMDM) (GIBCO, 
Carlsbad, CA, USA) supplemented with 10% human AB serum (Mediatech, Inc, Herndon, VA, 
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USA), 1% Penicillin-Streptomycin (GIBCO, Aukland, NZ, USA), 1% HEPES (Mediatech, Inc, 
Herndon, VA, USA), 1% L-glutamine (Mediatech, Inc, Manassas, VA, USA), 50 g/mL human 
transferrin (Sigma, St. Louis, MO, USA) and 5 g/mL insulin (Sigma, St. Louis, MO, USA). The 
cells were kept in a 37C incubator with 5% CO2. 
For TLR-mediated activation, 5×10
6
 control B cells were plated in 5 mL of medium 
containing lipopolysaccharide (LPS) (0.5 ng/L, Alexis, San Diego. CA, USA), CpG (1 M, 
Hycult Biotech, Canton, MA, USA, the sequence of the CpG is 5’ tcgtcgttttgtcgttttgtcgtt 3’), or 
polyI:C (5 ng/L, Invivogen, San Diego, CA, USA) at 37C for 24 hours or 48 hours. For CD40 
activation, NIH-3T3 CD40L or NIH-3T3 feeder cells were cultured to confluency and then 
irradiated for 9K by Cs-irradiator. Irradiated feeder cells were plated in 6-well plates at 2×10
5
 
cells/mL, incubated overnight at 37C, and washed twice gently with PBS before adding  the B 
cell medium. Purified control B cells were co-cultured with the feeder cells at 37C for 24 hours 
or 48 hours. For BCR activation, purified control B cells were adjusted to 1×10
7
 cells in 0.1M 
phosphate buffered saline (pH7.2). Goat anti IgM  F(ab’)2 (Southern Biotechnology Associates, 
Birmingham, AL, USA) at 10 g/mL was added to untransformed B cells for 20 minutes on ice. 
These cells were transferred to human B cell medium and cultured for 24 hours or 48 hours at 
37C. 
For experiments involving inhibitors for the c-jun N-termina kinase (JNK) or mitogen-
activated protein kinase/ERK kinase (MEK), cells were co-cultured with the JNK inhibitor 
SP600125 (50 M, A. G. Scientific, Inc., San Diego, CA, USA) or MEK inhibitor PD98059 (50 
M Sigma, St. Louis, MO, USA) for 24 hours before the isolation of RNA for RT-PCR assays. 
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Total RNA preparation 
Total RNA from control B or CLL cells was extracted by the Trizol method (Invitrogen, 
Carlsbad, CA, USA). Dried RNA pellets were re-suspended in appropriate volumes of 
DEPC/ddH2O. RNA was quantitated by OD 260/280 using a DU640 spectrophotometer (Beckman). 
MiRNA expression profiling 
We first profiled 435 miRNAs from 22 CLL samples and 1 control B sample by the 
Luminex method using sequential adapter ligation and gel extraction  as described [52]. To 
expand our sample size, we then chose 43 miRNAs which were predicted to be differentially 
expressed in CLL from our previous data, 4 miRNAs from published data, and 3 control miRNAs 
for large scale profiling with the FlexmiR miRNA labeling kit (Luminex, Austin, TX, USA, as 
described [116]). In this method, 2.5 g of total RNA was labeled with biotin, and then it was 
hybridized with locked nucleic acid (LNA)-modified capture probe coupled with beads. After 
washing away the unbound RNA samples, streptavidin-phycoerythrin (SAPE) reporter molecules 
were added to the reaction and the expression of miRNAs was analyzed on Luminex analyzer. 
Data analysis for miRNA profiling 
A mock array was generated by averaging the expression of each miRNA in all samples. 
Next, a linear correction for each sample to the mock array was performed. The data were 
analyzed using GenePattern software from the Broad Institute. miR-146b-5p was deleted from the 
analysis due to abnormally high background bead signals. 
Gene set enrichment analysis 
A  B cell miRNA activation signature was defined as as miRNAs that were significantly 
altered with a t-test p-value of <0.05 after correction for multiple comparisons in control versus in 
vitro activated B cells. We performed independent GSEA analysis for upregulated and 
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downregulated miRNA sets to test for enrichment of activation signature miRNAs in control B 
cells versus CLL profiles as described in [117]. 
MiRNA-specific RT-PCR assay 
Total RNA was treated with DNase I (Ambion, Austin, TX, USA), and cDNA synthesis 
was carried out using miScript Reverse Transcriptase kit (Qiagen, Hilden, Germany). miRNA 
specific RT-PCRs were performed using the miScript primer assay according to the 
manufacturer’s protocol (Qiagen, Hilden, Germany). The relative expression of specific miRNAs 
was calculated by the Ct method. A randomly chosen subset of the CLL cell RNAs samples 
used for Luminex bead-based miRNA expression profiling were used for validation by RT-PCR-
based miRNA expression profiling. Full RT-PCR expression data is published in Li et al [98].  
Statistical methods 
Associations between miRNA expression and clinical characteristics were assessed using 
the Fisher exact test for binary variables, and the Kruskal-Wallis test for variables with three or 
more categories. Time to first therapy was calculated as time from initial diagnosis to first 
therapy; patients not yet treated were censored at date last known alive. Time to first therapy was 
estimated using the method of Kaplan and Meier; the log rank test was used to assess associations 
with time to first therapy. Recursive partitioning was used to identify an optimal binary split for 
each miRNA, using the rpart package in R. P-values from recursive partitioning are not adjusted 
for the optimization of the method. Two-sided p-values are not adjusted to reflect multiple 
comparisons; q-values reflect adjustment for multiple comparisons using the false discovery rate 
of Benjamini and Hochberg, as implemented in the q-value package in R. A false discovery rate 
of 0.10 or smaller was the criterion for reporting significant differences in both clinical features 
and time to first therapy in this study. 




Determinants of a CLL-specific miRNA expression signature 
We profiled miRNA expression across 38 highly purified CLL patient samples, 9 control 
B cell samples and 5 CpG activated B cell samples using the Luminex method [116]. CLL cells 
are characterized by expression of both CD5 and CD19 cell surface markers [118]. CD19 bead 
positive selection was used to purify CLL cells and greater than 97% CLL cell purity was verified 
by FACS analysis of CD5 and CD19 expression for all samples used in this study. Unsupervised 
hierarchical analysis clustered CLL samples based upon miRNA expression (Figure 3.1A). 
Comparative marker analysis in CLL samples compared with control B samples identified a 
CLL-specific miRNA signature consisting of upregulation of miR-342-3p, miR-34a, miR-150, 
miR-29a, b, and c, let-7g, miR-26a, miR-101, and miR-155, and downregulation of miR-15b, 
miR-103, miR-27b, miR-24, miR-23a, miR-223, and miR-181a and b. (Figure 3.1B). 
Though most B cells are CD5-CD19+, specific subsets of B cells (e.g. peritoneal, 
tonsillar) are CD5+CD19+. To verify that miRNA expression profiling discerned differences 
between normal CD5-CD19+ B cells and CD5+ CD19+ CLL cells rather than between normal 
CD5-CD19+ and CD5+CD19+ B cells, control B cells from 4 different control donors were 
sorted into CD5- and CD5+ populations and RT-PCR analysis was performed. Our data indicate 
that miR-181a and miR-181b were downregulated in 6 CLL samples relative to both CD5- and 
CD5+ control B cell populations. Similarly, miR-29a, miR-150, and miR-155 were upregulated 
in CLL relative to both CD5- and CD5+ control B cell populations. This indicates that CD5+ 
expression status does not affect the interpretation of the changes in miRNA expression in these 
studies.  




Figure 3.1:  miRNA expression accurately classifies control B cell, activated B cell, and CLL 
samples.  A) Heatmap of miRNA expression across 38 patient-derived CLL samples, 9 donor B 
cell samples, and 6 CpG activated donor B cell samples. miRNA expression is hierarchically 
clustered on the Y-axis and patient-derived CLL samples or control B cell donors are 
hierarchically clustered on the X-axis. The relative expression of miRNAs is depicted according 
to the color scale shown on the bottom. CB: donor control B sample; CB-act: donor B samples 
activated with CpG; CLL: CLL samples. B) Heatmap of miRNAs with differential expression in 
donor control B cells and CLL:  Differentially expressed miRNAs were identified by comparative 
marker selection. MiRNAs are grouped by comparative marker score. The relative expression of 
miRNAs is depicted according to the color scale shown on the bottom.
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miRNA alterations identify an activated B cell phenotype in CLL cells 
A number of the miRNAs identified as part of the CLL specific signature overlap with 
miRNA expression signatures we observed in T-cell development and activation.  Notably, the 
miR-26 and miR-29 familes, together with miR-150 and let-7g are upregulated during maturation 
of T cells (Figure 2.1C). However, the most differentially expressed miRNAs in CLL are those 
we previously associated with murine T cell activation. miR-181a is the most significantly 
downregulated miRNA in CLL cells as compared to unactivated B cells, and has been shown to 
be downregulated after T cell activation  (Figure 2.1B) [79], miR155 is strongly induced after T 
cell activation, and is the most significantly upregulated  miRNA in CLL cells relative to 
unactivated B cells (Figure 2.1D and 3.1B). We thus hypothesized that CLL cells may share a 
common pattern of miRNA mediated gene regulation with activated B cells. 
To systematically compare miRNA expression in CLL to the miRNA changes induced by 
B cell activation, we identified sets of miRNAs that were most significantly (p<0.05 after 
correction for multiple comparisons) upregulated or downregulated after untransformed B cell 
activation by CpG. The upregulated miRNAs were miR-34a, miR-198, miR-155, miR-337-3p 
and miR-342-3p and the downregulated miRNAs were let-7c, miR-15b, miR-20b, miR-103, miR-
181a, miR-181b, and miR-331-3p (Figure 3.2 A). We then performed gene set enrichment 
analysis (GSEA) for these upregulated and downregulated miRNAs in CLL versus untransformed 
B cells (Figure 3.2 B-E). Four out of seven downregulated miRNAs (miR-15b, miR-103, miR-
181a, and miR-181b) were expressed at lower levels in CLL, and five out of five upregulated 
miRNAs (miR-34a, miR-155, miR-198, miR-337-3p and miR-342-3p) were expressed at higher 
levels in CLL compared to untransformed B cells.  
To independently verify our Luminex profiling data and confirm a link between the 
miRNA changes observed in CLL and B cell activation, we tested expression of B cell activation  
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Figure 3.2:  GSEA reveals a B cell activation miRNA signature in CLL. A) Heatmap of B cell 
activation signature miRNAs comparing expression in unstimulated control B (CB) cells and 
CpG activated B cells (CB act). B) GSEA enrichment profile of downregulated B cell activation 
signature miRNAs in control B cells versus CLL cells. C) Heatmap of downregulated B cell 
activation signature miRNA expression in control B cells and CLL cells. D) GSEA enrichment 
profile of upregulated B cell activation signature miRNAs in control B cells versus CLL cells. E. 
Heatmap of upregulated B cell activation signature miRNA expression in control B cells and CLL 
cells. 
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Figure 3.2 (Continued) 
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induced and CLL signature miRNAs in activated B cells and CLL cells by RT-PCR. We purified 
B cells from healthy donors and stimulated these cells with a variety of B cell activators including 
-IgM and CD40L (BCR and T cell-assisted co-stimulatory pathways), and LPS, CpG, or 
polyI:C Toll like receptor (TLR) pathways and examined miRNA expression (Summarized in 
Table 3.1) [98]. For the CLL signature miRNAs, we found that activation of control B cells led to 
reduced miR-23a, miR-23b, miR-24, miR-27b, miR-181a, miR-181b, and miR-223 (all 
downregulated in the CLL signature) and increased miR-155 (upregulated in the CLL signature), 
regardless of the mechanism of B cell activation. Most miRNAs demonstrated consistently 
altered expression regardless of the mechanism of B cell activation though the expression of the 
miR-29 family varied depending upon B cell activation. Whereas -IgM and CD40L upregulated 
miR-29a, LPS, CpG, or polyI:C downregulated miR-29a. In contrast, -IgM and CD40L 
downregulated miR-29b and miR-29c but LPS, CpG, or polyI:C upregulated miR-29b and miR-
29c. miR-223 is increased in response to CD40L activation while decreased in response to other 
stimuli. Additionally, the expression of miR-26a was increased in CLL and only in B cells 
activated with CD40L but did not change in B cells activated with -IgM. These data suggest that 
particular CLL signature miRNAs are altered in response to specific B cell stimuli. In contrast, 
miR-150 was reduced during B cell activation, and upregulated in almost all the CLL samples 
tested (Figure 3.1 and Table 3.l). Thus, high expression of miR-150 may be CLL specific. 
To mechanistically link altered miRNA expression in CLL with altered expression of 
miRNAs observed in B cell activation, we carefully examined the expression of one miRNA 
(miR-155) whose expression is increased in CLL and in activated B cells. The miR-155 gene is 
activated upon B cell stimulation and contains binding sites for the AP-1 transcription factor. B 
cell activation stimulates the JNK pathway, increases the levels of phospho-ERK, and then 
activates AP-1 [119]. We confirmed that treatment of CpG activated B cells with either JNK or 
MEK inhibitor decreased the expression of miR-155 (Figure 3.3A). CLL cells express high 
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Table 3.1. Signature miRNA expression comparison between activated B cells and CLL 
cells relative to control B cells. 
miRNA list B cell Activation CLL 












































miR-223  /  
 
Relative expression of signature miRNAs in activated B cells and CLL cells was measured by 
RT-PCR. Up and down arrows indicate upregulation or downregulation of specific miRNAs, 
respectively, when compared to untransformed, control B cells. A parallel line indicates no 
change when compared to untransformed, control B cells. miR-26a is unaffected by IgM 
stimulation, but upregulated in response to other B cell activators. miR-223 is upregulated by 
CD40L simulation, but downregulated by other B cell activators.  




Figure 3.3: Inhibition of miR-155 expression by MEK and JNK inhibitors. A. Relative 
expression of miR-155 in CLL cells treated with MEK (PD98059; PD) and JNK (SP600125; SP) 
inhibitors. B. Relative expression of miR-155 in CpG-activated B cell treated with PD98059 and 
SP600125 inhibitors. Cells were cultured with DMSO as a control (DMSO). 
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steady state levels of miR-155, and treatment with JNK or MEK inhibitors decreases miR-155 
expression (Figure 3.3 B). These data indicate common signaling pathways lead to altered 
miRNA expression in activated B cells and CLL cells. 
Signature miRNA alterations are associated with clinical features and time to first 
therapy 
Previous reports suggest that altered miRNA expression has prognostic value [120-122]. 
 
ZAP70 and IgVH mutational status are strongly associated with clinical outcome for CLL 
patients. Thus, comparative marker alignments were performed to identify miRNAs clustered by 
ZAP70 and IgVH status (Table 3.2 A and B). Out of 38 patients, we examined 14 ZAP70
+
 patients 
and 14 IgVH unmutated patients. We found that miR-150 was upregulated in ZAP70
+
 patients 
whereas miR-29c and miR-223 were upregulated in both ZAP70
-
 and in IgVH mutated patients 
suggesting that decreased levels of miR-150 and increased levels of miR-29c and miR-223 may 
be associated with better clinical outcomes. Our data do not indicate a statistically-significant 
correlation between miR-29c and miR-223 with any established cytogenetic abnormalities used to 
distinguish CLL patient sub-populations, such as 17p, 11q and 13q deletion and trisomy 12 (data 
not shown). Additionally, miR-92a was upregulated in ZAP70
-
 patients and let-7g was 
upregulated in IgVH mutated patients (Table 3.2 A and B).  
We also examined miRNA expression across CLL cells for association with time to first 
therapy in these patients. Using recursive partitioning analysis for finding optimal cut points for 
miRNA expression, we examined time to first therapy. We identified two miRNAs (miR-29c and 
miR-223) with q-values of 0.07 associated with an optimized binary split (Kaplan-Meier curves 
and the optimal splits are indicated (Figure 3.4)). CLL patients with lower expression levels of 
these miRNAs demonstrated shorter time to first therapy compared to CLL patients who did not 
demonstrate this pattern of miRNA expression. Decreased expression of these two miRNAs was 
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also associated with ZAP70
+
 and IgVH unmutated patients (Table 3.2 A and B) implying poor 
prognosis.
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Table 3.2 A. miRNAs correlated with ZAP70 status. 
 
miRNAs 
ZAP70   
Negative Positive p q 
N Median (Min, Max) N Median (Min, Max)   
miR-150 22 13.67 (13.16, 14.89) 14 14.05 (13.64, 15.05) 0.009 0.09 
miR-223 22 11.28 (10.08, 11.98) 14 10.81 (9.47, 11.23) 0.005 0.08 
miR-29c 22 12.13 (10.99, 12.53) 14 11.62 (10.90, 12.13) 0.006 0.09 
miR-92a 22 11.10 (10.81, 11.72) 14 10.95 (10.40, 11.24) 0.004 0.08 
 




        IgVH mutation   
Mutated Unmutated p q 
N Median (Min, Max) N Median (Min, Max)   
let-7g 17 12.01 (11.54, 12.33) 14 11.79 (11.22, 12.34) 0.005 0.07 
miR-223 17 11.29 (10.62,11.98) 14 10.65 (9.47, 11.07) 0.0005 0.02 
miR-29c 17 12.20 (11.25, 12.53) 14 11.49 (10.90, 12.25) 0.004 0.06 
Wilcoxon rank sum tests were used to identify differences on miRNA expression pattern between 
patients with different clinical features such as ZAP70 status (3.2 A), and IgVH status (3.2 B). p-
value and q-value for each miRNA are shown. N: patient number 
 




Figure 3.4: The expression of miR-29c and miR-223 is associated with time to first therapy 
in CLL. A shorter time from diagnosis to initiation of first therapy is significantly associated with 
reduced expression of miR-29c and miR-223. A recursive partitioning approach identifies the 
optimal split for each miRNA: miR-29c expression at 11.82 or lower is associated with shorter 
time to first therapy, q = 0.07. miR-223 expression at a level of 11.14 or lower is associated with 
shorter time to first therapy, q = 0.07. 
  




miRNA expression profiling has been used to identify signatures that classify CLL [108-
110, 123]. Interestingly, none of these published signatures are identical. The reasons for the 
different miRNA signatures are unknown. Different methods and different miRNA analysis 
platforms may partly explain the different signatures identified by each of these groups. Calin et 
al. profiled 94 CLL patient samples using a miRNA microarray but did not purify CLL cells to 
homogeneity [108, 109]. Fulci et al. profiled 56 CLL patient samples by cloning and SYBR-
green-based RT-PCR [110]. Zanette et al. profiled miRNA expression in 9 CLL patients and 6 
healthy donors using TaqMan-based miRNA assays [111]. In addition, CLL is a heterogeneous 
disease and it is possible that different patient populations have unique miRNA expression 
patterns. Zhang et. al. [112] demonstrated CLL cells are more like memory B cells based on 
miRNA profiling, whereas our miRNA profiling data associated CLL cells with miRNA changes 
induced during early activation of B cells. 
The uniformity of miRNA expression changes we observed in CLL patient samples 
relative to B cells is striking (Figure 3.1). Though the directionality of changes in expression is 
consistent for these particular miRNAs, the magnitude of changes varies considerably for these 
particular miRNAs. Indeed, some miRNAs demonstrate expression variance over several orders 
of magnitude. This variability in expression of these miRNAs may be related to the 
heterogeneous clinical course. Another striking finding is that many CLL signature miRNAs 
demonstrate similar trends in activated B cells regardless of the mechanism of activation. 
However, certain CLL signature miRNAs are differentially regulated by specific B cell 
activators. We show that miR-29b and miR-29c are downregulated by IgM and CD40L activation 
but are upregulated with TLR activation. Published reports on miRNA expression in naïve, 
germinal center, memory, and plasma B cell populations indicate that these miRNAs are also 
differentially regulated during B cell differentiation [112, 124]. miR-29c is reduced in germinal 
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center B cells [112] and in centroblasts [124] but is increased in memory B cells [112]. The 
pattern of miR-29 family member expression may be affected by the duration of B cell activation 
or the simultaneous stimulation of multiple activation pathways during the germinal center 
reaction.  Interrogating the causes and consequences of altered miRNA expression in CLL cells in 
common with and distinct from altered miRNA expression in activated B cells will improve our 
understanding of this disease. 
We identify a correlation between miR-29c and miR-223, negative clinical markers, and 
shorter times to first therapy. These observations are consistent with previous observations that 
have associated reduced levels of these two miRNAs with ZAP70, IgVH unmutated status, and 
poor clinical outcomes. [109, 110, 122, 125]. In addition, CLL patients expressing CD38 tend to 
have higher expression of activated cellular markers, including CD27, CD62L, CD69 and Ki-67, 
and this activation status is correlated with poor clinical outcomes [126, 127]. Our study 
integrates these two observations. We found that clinically relevant alterations in miR-29c and 
223 are part of a larger pattern of miRNA changes consistent with B cell activation  
miR-29c and miR-223 co-vary with other clinical parameters and thus may not have 
independent prognostic value, but these miRNA changes may have biological function in CLL. 
BCR activation led to downregulation of miR-29c and miR-223 and ZAP70 is associated with 
increased BCR signaling in CLL [128]. Although the kinase domain of ZAP70 is not required for 
BCR pathway stimulation in CLL, the scaffolding function of ZAP70 acts as an adaptor that 
clusters and thereby increases signaling through BCRs in CLL [128, 129]. It is likely that the 
association we observed with ZAP70+ CLL and lower miR-29c and miR-223 is due to enhanced 
BCR signaling mediated by ZAP70 [128]. Reduced levels of miR-29c have been shown to de-
repress expression of MCL-1 and TCL-1, known oncogenes implicated in the CLL -apoptotic 
defect [120, 121, 123]. This downregulation of miR-29c may play an important role in the poor 
clinical outcomes associated with ZAP70+ CLL.  
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Other miRNA changes consistent with B cell activation may also have an important role 
in CLL oncogenesis. miR-155 is strongly upregulated in all CLL samples tested as compared to 
control B cells, is increased in multiple cancers [130-132], and promotes B cell lymphomagenesis 
[133]. Conversely, miR-181a and miR-181b are strongly downregulated in all CLL samples 
tested.  PI-3K is a predicted target of miR-181a and miR-181b [21] and the PI3K pathway has 
been implicated in the apoptotic defect in CLL cells [134]. These data suggest that miR-155 has 
an oncogenic function, whereas miR-181a and miR-181b have a tumor suppressive function in 
CLL. Analysis of changes in miRNA expression and their target genes during B cell activation 
and CLL oncogenesis will provide insights into the physiological roles of these miRNAs. 
Understanding the roles of miRNAs in the dysregulated gene networks that underlie the 
pathology of CLL could enable the application of miRNA-based therapeutics for this common 
leukemia. 














Dynamic microRNA expression during CD8 T cell activation:  








Cytotoxic CD8 T cells are important mediators of the adaptive immune response. 
However, miRNA expression signatures and the roles of individual miRNAs during the CD8 T 
cell response are poorly characterized. We demonstrate dynamic changes in miRNA expression 
during early CD8 T cell activation, including decreased expression of miR-150, miR-26, miR-29 
and miR-30, and increased expression of miR-155, miR-31, miR-146 and the miR-17-92 cluster. 
We show that miR-31 is strongly induced by calcium/Calcineurin-dependent processes during T 
cell activation, with highest induction in CD8 T cells. miR-31 expression is maintained in CD4 
and CD8 memory T cell populations generated in vitro and in vivo. We identify miR-31 targets in 
CD8 T cells, including Lats2, Ppp6c, Stk40, Sh2d1a, Ilf3, and Cdkn1a, and propose a model 
whereby miR-31 induction primes CD8 T cells for activation by repressing inhibitors of multiple 
activation-induced pathways.  




CD8 T cells are essential effectors of the adaptive immune response to viruses and 
intracellular pathogens capable of inducing the death of infected somatic or tumor cells. The CD8 
T cell response is characterized by rapid, dramatic shifts in cellular function and gene expression. 
Naïve CD8 T cells are quiescent, with low metabolic activity, little to no cell division, and 
virtually no cytotoxic activity. After TCR engagement by a cognate peptide-MHC complex, these 
cells expand more than 1000 fold, and rapidly acquire a panel of effector functions, including 
cytolytic activity and cytokine production [135, 136]. Underlying this transition are changes in 
multiple gene networks affecting survival, proliferation, effector function, and cell trafficking. 
Microarray mRNA expression profiling has been used to discover the genes and pathways which 
drive CD8 T cell differentiation and activation [137, 138]. Given the important roles of miRNAs 
in developmental transitions, it is likely that they are also involved in CD8 T cell activation. 
Strong evidence for this role comes from conditional deletion of Dicer, an RNaseIII enzyme that 
is required for the biogenesis of almost all miRNAs. Deletion of Dicer during T cell development 
in the thymus leads to a dramatic reduction in CD8 T cell levels in the periphery [67, 139]. Loss 
of Dicer in mature CD8 T cells leads to enhanced activation and proliferation in vitro, but a 
dramatically reduced CD8 T cell effector response in vivo [140]. These results clearly show that 
miRNAs play important roles in CD8 T cell development and function.  
Two groups have profiled miRNA expression in CD8 T cells that were induced to 
differentiate towards an effector or central memory phenotype in vitro by culture with antigen and 
IL-2 or IL-15 [141]. Almanza et al. compared miRNA expression by microarray in differentiated 
subsets after antigen stimulation [142]. They identified miRNAs with differential expression in 
memory subsets, including miR-150, miR-155, and members of the let-7 family, and proposed a 
model whereby high miR-150 and low miR-155 promotes development of central memory cells. 
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Wu et al. profiled miRNAs in naïve, effector and central memory subsets by small RNA cloning 
and microarrays [143]. They report a global downregulation of the majority of miRNAs during 
transition from naïve to effector memory subset, with a more modest downregulation during 
transition from naïve to central memory subset. Wu et al. report upregulation of only a few 
miRNAs in memory subsets relative to naïve subsets, most notably miR-21. The paradigm of 
lower global miRNA activity in CD8 T cells is consistent with other changes in gene regulation 
seen during T cell activation. Deep sequencing of transcripts has revealed that proliferating T 
cells tend to use more proximal polyadenylation sites, leading to shorter 3’UTRs [144]. As most 
miRNA target sites are in the 3’UTRs, shortening of 3’UTRs may synergise with lower miRNA 
levels and lead to a general loss of miRNA-mediated repression. Given the limited number of 
miRNA profiles available for the process of CD8 T cell activation and lack of consensus 
regarding the miRNA activation signature in these cells, additional studies of the changes in 
miRNA expression are needed to determine the roles of miRNAs in the CD8 T cell response.  
Individual miRNAs have been shown to play important roles in T cell activation. miR-
146a and miR-155 are strongly induced after activation of both innate and adaptive immune cells, 
including CD8 T cells. Both of these miRNAs participate in a negative feedback loop regulating 
NF-kB signaling, and are required for optimal Treg function [145-147].  In addition, both miR-
146a and miR-155 are involved in regulation of cytokine signaling. miR-146a downregulates type 
1 interferon (IFN) signaling by repressing the key signaling intermediates Traf6, Irak1/2 and 
Stat1 [51, 145]. In contrast, miR-155 upregulates cytokine signaling by repressing the Socs1 
suppressor of cytokine signaling, and promotes Th1 type development [44, 147].  The 
downregulation of miRNAs expressed in naïve T cells can also play important roles in T cell 
activation. For instance, miR-29c is downregulated in activated NK cells, CD4 T cells, and CD8 
T cells relative to naïve T cells. miR-29 inhibits interferon- production either directly by 
repressing the interferon-mRNA itself, or indirectly by repressing upstream transcription factors 
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essential for interferon- expression [148, 149]. The release of interferon-from inhibition by 
miR-29c after activation promotes secretion of this important cytokine. 
However, the roles of the majority of the miRNAs expressed in T cells are still unknown. 
In this study, we profile miRNA expression during early CD8 T cell activation, and identify miR-
31 as novel activation-induced miRNA in mouse T cells. miR-31 is induced after TCR 
stimulation in a calcium-dependent manner, and continues to be expressed in memory cell 
populations in vitro and in vivo. We identified mRNA targets of miR-31 in primary T cells, which 
include pro-apoptotic factors and negative regulators of cyclin, NF-B and MAPK signaling. We 
propose a model whereby miR-31 induction primes cells for activation by promoting T cell 
survival, activation, and proliferation.  
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Materials and methods 
Mice 
Male c57bl/6 and OT-I TCR transgenic mice between 5-10 weeks of age were purchased 
from Taconic Farms (Hudson, NY, USA). Foxp3-GFP reporter mice were obtained from Dr. 
Vijay Kuchroo.   
Isolation of immune cell subsets 
CD8 T cells were isolated by negative selection using EasySep beads (Stemcell 
technologies, Vancouver, BC, Canada.). B cells and NK cells were isolated from mouse spleen 
and peripheral lymph nodes by FACS. B cells were sorted as CD19+/B220+ and NK cells as 
DX5+/CD3-.  Endogenous activated, memory, and Treg T cell populations were isolated from 
spleen and PLN by FACS. Naïve and memory cells were sorted from CD4 and CD8 as: naïve 
(CD4/8+ CD62L+ CD44+ CD25-); central memory (CD4/8+ CD62L+ CD44+ CD25-); effector 
memory (CD4/8+ CD62L- CD44+ CD25-). Treg cells were sorted as CD4+ CD25+ GITR+. In 
vivo activated CD8 cells were sorted as CD8+ CD25+. Foxp3GFP+ and Foxp3GFP- CD4 T cells 
were isolated from Foxp3GFP reporter mouse splenocytes stained with -CD4.  Anti B220, 
CD19, CD25, DX5 and CD3 antibodies were obtained from Biolegend (San Diego, CA, USA). 
Anti CD4, CD8, CD62L, CD69 and CD44 antibodies were obtained from eBioscience (San 
Diego, CA, USA) 
Cell culture and activation 
Cells were cultured in RPMI-1640 Medium supplemented with 10% fetal calf serum, 50 
units/ml Penicillin-Streptomycin,10 mM HEPES, 2 mM L-glutamine, and 55 M -mercapto-
ethanol (all from GIBCO, Carlsbad, CA, USA) in a 37°C incubator with 5% CO2. T cells were 
activated with 10 g/ml plate bound -CD3 with or without 2 g/ml soluble -CD28 antibodies 
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(eBioscience, San Diego, CA, USA) or 500 nM ionomycin. Cyclosporin A was added at 250 
ng/ml. NK cells were activated with PMA (5 ng/ml) and ionomycin
 
(500 nM). B cells were 
activated with 20 ng/ml IL-2, 1 g/ml -IgM (Southern Biotech, Birmingham, AL, USA) and 
3g/ml CpG 2006.  Murine T hybridoma cells were isolated as described [150]. 
Luminex profiling of miRNA expression 
MiRNA expression was profiled as described in Chapter 2.  
MiRNA-specific RT-PCR assay 
MiRNA specific cDNA synthesis from total RNA was carried out using MicroRNA 
Reverse Transcription Kit (Applied Biosystems, Carlsbad, CA, USA) miRNA-specific RT-PCRs 
were performed using Taqman miRNA assays according to the manufacturer's protocol (Applied 
Biosystems, Carlsbad, CA, USA). miRNA expression was calculated using the Ct method 
with using miR-16 as an expression standard.  
NFAT binding site prediction and chromatin immunoprecipitation 
Computational prediction of NFAT binding sites was performed using the Lever 
algorithm [151]. NFAT chromatin immunoprecipitation was performed as described. [152]. 
Briefly, chromatin fragments from untreated and -CD3/CD28 treated (24 hrs) primary CD8 T 
cells were immunoprecipitated with 6 g of a-NFAT antibody sc-5499 (Santa Cruz 
Biotechnology, Santa Cruz, CA, USA). DNA extraction was performed using a Qiagen 
purification kit. Site enrichment was analyzed by RT- PCR using the following primers:  
forward: 5'-TATAGGGGATGGTTTGGGAAT-3 
reverse: 5'-ACCAAGAGCTTTTACACGTCCT-3' 
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Lentiviral infection, microarray profiling, and miR-31 target gene prediction  
SiRNA containing lentiviral vectors against murine Lats2, Ppp6c, Stk40, and Sh2d1a 
were obtained from the RNAi Consortium and subcloned into the Plko.3G vector. miR-31 
precursor sequence was generated by primer extension, and directly cloned into the Plko.3g 
vector using EcoRI/PacI enzyme digest. Empty Plko.3g constructs were used as controls for 




CD8 T cells were purified from OT-I mice (Taconic, Hudson, NY, USA) by negative 
selection using EasySep beads (Stemcell technologies, Vancouver, BC, Canada). Purified T cells 
were cultured for 2 days in RPMI-10 with 100ng/ml IL-15 and 1 ng/ml Il-7 (R&D biosystems 
Minneapolis, MN, USA). Cells were infected with lentiviral vectors at a MOI of 10:1 by spin 
infection in Retronectin coated plates (Takara Bio, Otsu, Shiga, Japan). After infection, cells were 
cultured for 3 additional days in RPMI-10 with 10 ng/ml Il-2 (R&D biosystems Minneapolis, 
MN, USA). GFP+ cells from 4 independent cultures per condition were then sorted by FACS and 
RNA isolated with Trizol followed by cleanup with RNeasy columns (Qiagen Valencia, CA, 
USA). 10 g RNA/condition were profiled on Affymetrix Mouse Genome 430 2.0 Arrays. Array 
data analysis was performed using DCHIP, followed by Significance Analysis of Microarrays to 
isolate differentially expressed genes [153, 154]. A master list of miR-31 target genes was 
generated using the union of mouse miR-31 target predictions from Targetscan, Starbase, Rna22, 
Pictar and Miranda [155-159].  
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Luciferase Reporter Assay 
3’ UTR sequences containing predicted target sites and at least 500 base pairs of flanking 
sequence were cloned downstream of a firefly luciferase reporter in the pcDNA3.1 mammalian 
expression vector. 293T cells were transfected in a 96-well format with 20 g Firefly reporter, 20 
g control pcDNA3.1 renilla luciferase reporter, and 200 g of control or miR-31 Plko.3g vector. 
Luciferase activity was quantified at 24 hours with DualGlo reagents (Promega, Madison, WI, 
USA) 
Western blotting 
Cells were lysed in RIPA buffer with P8340 protease inhibitor cocktail (Sigma St. Louis, 
MO, USA), 100 M phenylmethanesulfonylfluoride, and 10 mM sodium orthovanadate. An 
equal number of cells per lane were run on NuPage 12% Bis-Tris gels (Invitrogen) and 
transferred to polyvinylidene fluoride membranes using a mini-trans blot apparatus (BioRad, 
Hercules CA, USA) according to the manufacturer’s instructions.  Antibodies to Sh2d1a (Fl-128) 
and CD3 (m20) were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). 
 Antibodies to Ppp6c and Ilf3 were obtained from Abcam (Cambridge MA, USA). Antibodies to 
alpha-tubulin, ERK1/2, phospho-ERK1/2, phospho-Mek, and phospho-p38 were obtained from 
Cell Signal (Danvers, MA, USA). 




Early CD8 T cell activation induces dynamic changes in the expression of many 
miRNAs 
Current data on miRNA expression in CD8 T cells is inconclusive and has focused on 
miRNA expression in in vitro generated memory subtypes. However, many of the most dramatic 
changes in gene expression and cellular phenotype occur early after T cell activation. To 
determine which miRNAs participate in T cell development and activation, we used a Luminex 
bead-based system to profile murine miRNA expression in developing thymocytes, mature T and 
B cells, CD8 T cells at 1 and 4 days post-activation, bone marrow-derived dendritic cells (DC), 
and control kidney and liver tissue perfused to remove contaminating lymphocytes. Profiling data 
indicate that expression of a large number of miRNAs is altered during early CD8 T cell 
activation (Figure 4.1A) and reveal a novel dynamic regulation of miRNAs during early CD8 T 
cell activation.  
miRNA alterations include the downregulation of miR-181a, miR-30 (e and d), miR-26 
(a and b), miR-150, miR-29 (a and c) and miR-466 as well as the upregulation of miR-92, miR-
146a, miR-296, miR-17, miR-18a, miR-320, miR-298, miR-132, miR-193a, miR-31 and miR-
155. In general, miRNA downregulation was more pronounced at 4 days post-activation, whereas 
many of the upregulated miRNAs were near peak values at 1 day post-activation. The slower 
detection of downregulation is likely due to long miRNA half-lives and thus the requirement for 
miRNA turnover and dilution though cell division to remove pre-existing miRNAs. A second 
general feature of CD8 T cell activation is the concurrent regulation of multiple members of the 
same miRNA family, similar to what we observed during T cell development. Multiple members 
of the miR-30, miR-26, and miR-29 families of miRNAs are concurrently downregulated. Given  





Figure 4.1: Signature changes in miRNA expression during early mouse CD8 T cell 
activation from Luminex profiling. A) miRNAs induced or suppressed at least 2.5 fold after 
CD8 T cell activation. miRNAs are ranked by fold change after activation. B) Expression of 
signature miRNAs in other mouse tissue types, including total thymocytes (Thy), B cells, T cells, 
bone marrow derived DC, LPS-stimulated DC, kidney, and liver.
   
64 
 
the overlapping mRNA targets of miRNA family members, it is likely that reduction in the levels 
of multiple family members is required for maximum functional impact. 
Some miRNAs we identify as being altered during CD8 T cell activation have known 
functions in the immune response. Among the downregulated miRNAs, the miR-26 and miR-29 
family members have been shown to repress cytokine genes [148, 149, 160, 161], and miR-181a 
regulates sensitivity of TCR to triggering by repressing inhibitory phosphatases [79]. The 
upregulated miRNAs miR-17, miR-92, and miR-18a are derived from the miR-17-92 cluster on 
chromosome 13. This miRNA cluster is essential for B cell development, and ectopic expression 
is associated with cellular proliferation, hyperactivation and autoimmunity [162, 163]. As 
previously described, miR-146a and miR-155 play important roles in modulating the immune 
response. In general, the changes in miRNA expression we observe during early CD8 T cell 
activation prime the CD8 T cell effector activity by decreasing negative regulators of cytokine 
secretion and increasing positive regulators of general cytokine signaling, proliferation, and 
activation. Simultaneously, by reducing the sensitivity of CD8 T cells to TCR stimulation and 
inflammatory cytokines through downregulation of miR-181a and upregulation of mir-146a, 
miRNAs are exerting a negative feedback effect to limit the immune response.  
 However, the roles of many of the altered miRNAs detected during early T cell activation 
remain unknown. In particular, the second most upregulated miRNA in our profile, miR-31, does 
not have a known role in CD8 T cells. In contrast to other upregulated miRNAs with known 
functions in both T cell and innate immunity, miR-31 is not expressed in unstimulated or LPS 
stimulated bone marrow DCs (Figure 4.1B). Given that this miRNA displayed strong 
upregulation after activation and a strong T cell expression bias, we decided to investigate miR-
31 in more detail. 
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miR-31 is expressed in activated and memory T cells and NK cells, but not in B cells.  
To determine if miR-31 induction is specific to T cells, we measured miRNA induction 
in other related immune cell types by RT-PCR (Figure 4.2A). Consistent with our Luminex 
profile, we observed strong upregulation of miR-31 in CD8 T cells after-CD3/28 stimulation. 
We also observed upregulation of miR-31 in CD4 T cells stimulated by -CD3/28 and in NK 
cells stimulated by PMA/ionomycin, although the magnitude of upregulation was significantly 
lower compared to that observed in CD8 T cells. Interestingly, we did not observe an increase in 
miR-31 expression in B cells after activation with -IgM antibody and CpG oligonucleotides. 
These  data suggest that miR-31 plays a role in T cell specific processes.  
 Time course experiments revealed that an increase in mature miR-31 is detectable as 
early as 4 hours after CD8 T cell activation (Figure 4.2B).  To determine if miR-31 expression 
was limited to early activation or persisted in differentiated CD8 T cell subsets, we tested miR-31 
expression in memory T cells generated in vitro and in vivo. TCR transgenic CD8 T cells can be 
induced to differentiate in vitro towards effector memory or central memory phenotypes by 
antigen stimulus followed by culture with Il-2 or Il-15 cytokines [141]. We generated effector and 
central memory cells in vitro from OT-I CD8 TCR transgenic T cells, confirmed by FACS 
surface marker expression of CD62L- CD44+ (effector memory) and CD62L+ CD44+ (central 
memory), and tested miR-31 expression at multiple time points (Figure 4.2C). miR-31 expression 
was maintained at very high levels during in vitro differentiation into effector cells compared to 
naïve T cells. In contrast, miR-31 levels progressively declined during in vitro differentiation into 
central memory cells, although expression levels remained higher than that seen in naïve cells. 
While cytokine signaling may play a role in maintaining miR-31 levels, it is not sufficient for 
miR-31 induction, as treatment of CD8 T cells with Il-2, Il-7, or Il-15 cytokines without TCR 
stimulation did not alter miR-31 expression (data not shown). These data indicate that CD8 T cell 
differentiation state regulates the long-term expression of miR-31 after antigen stimulation.  




Figure 4.2: miR-31 expression depends on cell type and differentiation state. A) Relative 
miR-31 levels 24 hours after activation of CD4 or CD8 T cells with -CD3/CD28, NK cells with 
PHA/ionomycin, or B cells with -IgM/CpG. B) Relative miR-31 levels after stimulation of CD8 
T cells for 0hours (no tx), 4hr, 8hr, or 16 hours with -CD3/CD28. C) miR-31 expression in 
antigen-stimulated OT-I CD8 T cells cultured with the indicated cytokines to induce in vitro 
differentiation into effector and central memory phenotypes. miR-31 expression is given relative 
to that in OT-I cells prior to stimulation. D) miR-31 is expressed at elevated levels in both CD4 
and CD8 central memory (CM), effector memory (EM), CD4 CD25 GITR regulatory (Treg), and 
CD8 CD25 in vivo activated T cell populations.  E) miR-31 expression in Foxp3-GFP+ and 
Foxp3-GFP- CD4 T cells from Foxp3-GFP reporter mice. 
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Figure 4.2 (Continued) 
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 To confirm that the miR-31 expression we observed during in vitro differentiation is 
representative of in vivo expression patterns, we measured expression of miR-31 in sorted 
populations of naïve, effector memory, and central memory populations of CD4 and CD8 T cells, 
as well as CD4 regulatory T cells (Treg) and in vivo activated CD25+ CD8 T cells (Figure 4.2D). 
Endogenous CD8 effector memory and central memory populations expressed elevated levels of 
miR-31, with peak expression seen in circulating CD25+ CD8 T cells. The expression pattern of 
in vivo activated CD8 and central memory T cells closely paralleled the expression patterns we 
observed in vitro, with peak expression in activated T cells and maintenance of lower levels in 
central memory T cells. However, expression of miR-31 was not higher in effector memory 
compared to central memory CD8 T cells in vivo, suggesting that the Il-2 driven in vitro model of 
CD8 differentiation does not perfectly recapitulate in vivo differentiation patterns. Notably, 
similarly elevated miR-31 expression was also detected in CD4+ memory populations and in 
CD4+ CD25+ GITR+ Treg. The expression of miR-31 in Treg was confirmed in CD4 cells 
expressing the Foxp3-GFP reporter (Figure 4.2E). These results indicate that increased miR-31 
expression is a feature of memory cell differentiation in both CD4 and CD8 subsets.  
miR-31 expression during T cell activation is regulated by calcium and calcineurin 
signaling 
Research into the transcriptional regulation of miRNA expression has lagged behind the 
rest of the miRNA field. One important factor which complicates studies of the transcriptional 
regulation of miRNAs is identifying the primary transcript and transcriptional start site. While 
extensive information about the genomic position of miRNAs and their pre-miRNA hairpins is 
available, the long primary transcripts which give rise to intergenic miRNAs such as miR-31 are 
largely unknown. Processing of miRNA transcripts occurs co-transcriptionally, and the half-life 
of a mature primary transcript may be very short [164]. This appears to be the case for miR-31, as 
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no expressed sequence tag covers the miR-31 hairpin in mice. Sun et al. have published data 
indicating that miR-31 is expressed from a novel primary transcript in a mouse mesenchymal cell 
line [165]. However, we have not been able to confirm expression of this primary miR-31 
transcript in primary CD8 T cells, nor have we been able to identify an alternative primary 
transcript by 5’ rapid amplification of cDNA ends (RACE).  
Without knowledge of the primary transcript, it is difficult to conclusively define 
proximal promoter elements for miR-31 in CD8 T cells. However, analysis of the miRNA 
transcriptional units in humans suggests that many intergenic miRNA promoters are within 10 kb 
of the miRNA hairpin [151]. Given this data, and the fact that the miR-31 hairpin is more than 25 
kb from any known gene, we hypothesized that transcription factor binding sites within the 
vicinity of the miR-31 hairpin may play a role in regulating its expression.  We computationally 
identified potential transcription factor binding sites in the surrounding sequence using the Lever 
algorithm, which searches non-coding regions for clustered, evolutionally conserved regulatory 
motifs [151]. This search found a predicted NFAT site within a conserved region upstream of the 
miR-31 hairpin, at base pairs 88559195-88559213 of mouse chromosome 4 (Figure 4.3A).To 
show that this predicted site was active in CD8 T cells, we performed chromatin 
immunoprecipitation (CHIP) with -NFAT antibodies before and after T cell activation, followed 
by detection of the predicted site by RT-PCR. We found a strong enrichment in NFAT binding to 
the predicted site after stimulation of CD8 T cells with-CD3/CD28 antibodies (Figure 4.3B). 
This data suggested that NFAT signaling could play a role in the transcriptional activation of 
miR-31 during T cell activation.  
NFAT transcription factors are primarily regulated by calcium signaling through 
calmodulin and calcineurin. To connect miR-31 expression to NFAT regulation, we tested the 
effects of calcium signaling induction with the calcium ionophore ionomycin and suppression of 
calcium signaling through calmodulin with cyclosporine A (CyA). We found that treatment of  





Figure 4.3: Calcium signaling regulates miR-31 expression in CD8 T cells, potentially 
through an upstream NFAT binding site. A) An NFAT binding site is located in a strongly 
conserved region upstream of the miR-31 hairpin. B) CHIP for NFAT binding to predicted site 
before and after stimulation of CD8 T cells with  -CD3/CD28. C) 24 hour treatment of CD8 T 
cells with  -CD3/CD28 or ionomycin is sufficient to induce miR-31. D) Blocking calcium 
signaling with cyclosporin A (CyA) strongly inhibits miR-31 expression induced by 24 hour 
treatment with -CD3 or -CD3/28. 
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CD8 T cells with ionomycin was sufficient to induce miR-31 (Figure 4.3C). Blocking 
calcium/calcineurin signaling with CyA during T cell activation with -CD3 strongly inhibited 
miR-31 expression (Figure 4.3D). These data indicate that calcium signaling is both necessary 
and sufficient for induction of miR-31 during early T cell activation. 
miR-31 target gene identification 
Identification of the mRNA targets of a miRNA is an essential step to understanding its 
function.  miRNAs are capable of repressing  hundreds of mRNAs, but accurate target 
identification and validation is difficult due to the partial complementarity seen in mammalian 
miRNA/mRNA pairs, the relatively small change in mRNA/protein levels of each target, and the 
poor understanding of the factors which regulate miRNA binding. Although most computational 
algorithms predict hundreds to thousands of targets for each miRNA, only a small fraction of 
these predictions represent valid targets, and no current target prediction method successfully 
predicts all experimentally validated miRNA/mRNA pairs [166]. Given the high false positive 
rate present in computational predictions, experimental validation is essential for identifying true 
targets. 
MiRNA regulation reduces mRNA levels for the majority of target genes [167, 168]. 
Thus, ectopic expression of miRNAs followed by gene expression profiling is a useful technique 
for experimental target identification. To ectopically express miR-31 in primary CD8 T cells, we 
constructed a Plko.3g lentiviral vector expressing an experimentally validated Drosha substrate 
containing the miR-31 hairpin together with flanking sequence [169]. Empty Plko.3g vector was 
used as a control.  Naïve, resting mouse T cells are very difficult to infect with lentiviral vectors. 
To enable lentiviral infection without inducing endogenous miR-31, we pre-cultured OT-I TCR 
transgenic CD8 T cells with Il-7 and Il-15 for 2 days prior to infection. Following infection with 
empty or miR-31 vector, we cultured cells for an additional 3 days in Il-2 before isolation of 
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GFP+ transduced cells by FACS.  Gene expression in Empty- and miR-31-transduced T cells was 
profiled using Affymetrix 430 3’ microarrays, and genes differentially expressed in miR-31 
transduced samples were identified by Significance Analysis of Microarrays[154].  
Given the  inaccuracies of current target prediction methods, we utilized multiple 
computational algorithms to identify potential miR-31 target genes, including those that: require a 
stringent seed match (Targetscan); allow flexible seed match with G/U wobble base pair binding 
(Miranda, PicTar);  and allow seed match-independent motif identification (RNA22)  [155-157, 
159, 170]. Deep sequencing of Ago bound mRNA fragments has been proposed as a high-
throughput technique for experimental target validation, and the Starbase prediction method is 
based on results from this technique [158]. Using the union of predictions from these 5 methods, 
we found that probes downregulated in the presence of miR-31 were strongly enriched in 
predicted miR-31 targets, with 57% (39/68) of downregulated probes representing predicted miR-
31 targets (Figure 4.4A).  
To determine if predicted targets downregulated in array data were directly regulated by 
miR-31, we cloned the 3’UTRs of 13 cantidate target genes downstream of a luciferase reporter, 
and tested luciferase expression in the presence and absence of miR-31 (Figure 4.4B). We 
confirmed 11 3’UTRs in luciferase assays as being downregulated by more than 25% by miR-31 
in at least two separate assays.. Additionally, three luciferase-validated miR-31 targets (Ilf-3, 
Ppp6c, and Sh2d1a) were confirmed to be endogenous miR-31 targets by Western blotting 
(Figure 4.4C). Three of our luciferase-validated target genes (Ppp6c, Lats2, and Stk40) have been 
previously published as miR-31 targets in human solid tumors [171-173]. Eight additional 
luciferase-validated genes (Psd4, Sh2d1a, Ilf3, Coro7, Rab1b, Ppp6c, Stra13, and Cdkn1a) 
represent novel miR-31 targets. These new targets significantly expand the number of validated 
mouse miR-31 targets and provide insight into the potential role of miR-31 in CD8 T cell 
activation. 
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Figure 4.4: mir-31 target determination. A) Affymetrix profiling of Empty (control) or miR-31 
lentiviral vector-transduced CD8 T cells reveals a significant enrichment for predicted miR-31 
targets among probes downregulated upon miR-31 ectopic expression. B) Protein expression 
from control (Fl0x) and test luciferase reporters containing the 3’UTRs of target genes identified 
by Affymetrix profiling in the presence or absence of miR-31 reveals strong downregulation of a 
subset of hits. Data presented are results from two independent assays. 3’UTRs were scored as 
downregulated if they were significantly different from control Fl0x in (p<0.05) each assay, and 
displayed an average downregulation of at least 25%.  C) Western blots for  miR-31-mediated  
repression of endogenous protein levels. Western blots for protein expression in T cell hybridoma 
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miR-31 target gene functions 
One miR-31 target gene reveals an interesting aspect of miRNA-mediated regulation. Ilf3 
(interleukin enhancer binding factor 3) encodes at least 4 splice variants, grouped into short NF90 
and long NF110 gene products. The NF90 and NF110 mRNAs have different 3’UTRs, with only 
the NF110 variants containing a miR-31 site. In the presence of miR-31, expression of NF110 is 
selectively repressed leaving the expression of NF90 unaltered (Figure 4.4C). Ilf3 belongs to a 
cluster of transcription factors which bind to the proximal Il-2 promoter, and is required for the 
transcription and post-transcriptional stability of Il-2 and Il-13 [174, 175]. The NF90 splice form 
is thought to play the central role in cytokine transcription and stabilization. NF110 function is 
largely unknown despite experimental evidence indicating that NF110 is the most potent 
transcriptional activator of the Ilf3 family [176]. 
Of the confirmed target genes, the best studied are Ppp6c, Lats2, Sh2d1a, and Cdkn1a. 
Ppp6c is the catalytic subunit of protein phosphatase 6 (PP6). PP6 has been shown to regulate 
cyclin D1, stabilize IkB, and bind to the intracellular domains of CTLA4 and CD28 [177-179]. 
PP6 is also a major negative regulator of Tak1, the most commonly expressed Map3K7 member 
in the immune system [180]. Tak1 is essential for T cell development and homeostasis, where it 
regulates NF-K signaling and JNK/ERK activation [181, 182]. Lats2, large tumor suppressor 
homolog 2, is a Ser/Thr kinase which plays an important role in the Hippo signaling pathway 
[183]. Expression of Lats2 is linked to p53/p73 stabilization through negative regulation of the 
MDM2 E3 ubiquitin ligase, cell cycle arrest, and transcriptional upregulation of negative 
regulators of the MAPK pathway [184, 185].  Sh2d1a is a Sh2 domain containing adapter protein 
which is exclusively expressed in lymphocytes, with demonstrated expression in T cells, NK 
cells, and some B cell populations. Sh2d1a mediates signals from the signaling lymphocytic 
activation molecule family of immunomodulatory receptors. Knockout of Sh2d1a in the mouse 
leads to hyperproliferative T cell responses, defective activation induced cell death (AICD) , and 
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impaired T cell-B cell interactions [186, 187]. The cyclin dependent kinase inhibitor Cdkn1a 
(also known as p21, Waf1, or Cip1) is an negative regulator of cyclin activity and proliferation 
with important functions in the control of memory T cell homeostasis and secondary expansion 
[188]. Less is known about Stk40. However, it was originally identified as an inhibitor of TNF-
triggered NF-B activation and p53 activity [189]. miR-31 regulation leads to a small effect on 
the expression of each individual gene. However, if multiple target genes affect a common 
pathway, then miR-31 induction could significantly contribute to the phenotypic changes 
observed during T cell activation.  
These miR-31 regulated genes are involved in intersecting pathways with important 
functional roles in T cell activation. A model for the interaction between miR-31 target genes and 
downstream pathways is presented in Figure 4.5. Multiple target genes are negative regulators of 
ERK/MAPK and NF-B pathways, and we predict that these pathways will be de-repressed upon 
miR-31 induction. A second major focus is the p73 member of the p53 family of proteins, an 
important pro-apoptotic factor in T cells. Lats2 and Sh2d1a have both been associated with p73 
induction or stabilization, and NF-B signaling is crucial for preventing p73-driven cell death 
during T cell activation [186, 190, 191]. miR-31  induction thus may act to protect T cell from 
p73-mediated apoptosis through direct repression of Lats2/Sh2d1a coupled with indirect 
activation of NF-B. 
miR-31 Activates MAPK/ERK and Induces CD69 expression in a Murine T-hybridoma 
Our gene pathway model predicts that miR-31 de-represses ERK/MAPK signaling. We 
transfected a murine T-hybridoma cell line with empty and miR-31-expressing lentiviral vectors 
in order to test the effects of ectopically expressing miR-31. Surprisingly, expression of miR-31 
alone was sufficient to induce significant increases in MAPK pathway phosphorylation. The most  
 





Figure 4.5: Pathways regulated by confirmed miR-31 targets. miR-31 target genes are in 
green, affected genes and signaling pathways are in orange. Inhibitory pathways are depicted in 
red, activating pathways are depicted in black. 
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dramatic increases were seen in p42/44 ERK1/2 phosphorylation, but significant increases were 
also seen in MEK1 and p38 phosphorylation (Figure 4.6B). The expression of the CD69 
activation marker is driven by ERK/MAPK induction of AP1 transcription factor activity [192], 
and ectopic expression of miR-31 was sufficient to induce CD69. Lentiviral siRNA-mediated 
knockdown of two miR-31 targets, Lats2 and Ppp6c, phenocopied the effect of ectopic miR-31 
expression on CD69 (Figure 4.6A). This data supports a model where miR-31 expression de-
represses ERK/MAPK activation, and indicates that repression of Lats2 and Ppp6c by miR-31 
may be the major mediator of this effect.  
miR-31 inhibition in primary mouse T cells 
High levels of miR-31 expression are seen in CD8 T cells early after activation, and persist in 
memory populations. To experimentally investigate the physiological importance of miR-31 
induction during the immune response, it is essential to inhibit miR-31 activity. The primary 
experimental approach for inhibiting miRNA function is the transfection of single-stranded 
antisense inhibitory oligonucleotides, which bind stoichiometrically to mature miRNAs and block 
their function. However, the low transfectability of T cells presents a significant barrier to miR-31 
inhibition using this method. A number of publications have proposed experimental approaches 
to deliver inhibitory oligonucleotides to T cells [193-196]. In our hands, none of these methods 
effectively blocked miR-31 function in CD8 T cells. Genomic deletion is the definitive means for 
inhibiting gene expression, and we are in the process of developing miR-31 knockout mice.  
miR-31 was first cloned from embryonic stem cells and is expressed in solid tissues, 
raising the potential that complete loss of miR-31 could lead to developmental defects or an 
embryonic lethal phenotype [197]. To control for this possibility, we utilized a conditional 
knockout strategy, which places LoxP sites in the non-conserved regions flanking the miR-31 
hairpin (Figure 4.7A). A first round of c57bl/6 ES cell derived chimeras did not lead to germline  





Figure 4.6: miR-31 expression in a T-hybridoma cell line leads to induction of CD69 
expression and ERK/MAPK signaling. A) Expression of miR-31 or knockdown of miR-31 
targets Ppp6c and Lats2 induces CD69 expression in cultured murine T-hybridoma cells. Cells 
were stained with -CD69, and gated on GFP+ cells. B) Western blot for phospho-MAPK 
pathway members p38, p42/44 Erk1/2, Mek1, and control total p42/44 Erk1/2 in T-hybridoma 
cells transduced with control plko.3G or miR-31 expressing plko.3G.  





Figure 4.7: Conditional knockout of miR-31. A) miR-31 targeting construct inserts LoxP sites 
flanking miR-31 hairpin. Two locations for Southern blot probes outside of flanking sequence 
and relevant restriction enzyme digestion sites are shown.  B) Southern blots of ES cell DNA 
digested with Bgl2 for probe 1 and Stu1 for probe 2 confirm insertion of targeting construct in 
multiple JM8 ES cell line clones, including JM8-1 and JM8-2. C) PCR screening over the 
proximal LoxP site confirms germline transmission of the conditional miR-31 knockout allele in 
multiple offspring of chimeras derived from JM8-1 and JM8-2 ES cell lines.  
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transmission, but by utilizing the recently developed c57bl/6 JM8 ES cell line [198], we were 
able to efficiently generate recombinant ES clones (Figure 4.7B). Chimeras derived from 2 
independent JM8-derived clones displayed germline transmission (Figure 4.7C). We are currently 
breeding these mice to remove the neomycin resistance cassette, followed by crosses with Lck-
cre to induce a T cell-specific knockout and with Zp3-cre to induce a complete knockout.  These 
knockouts will allow us to unequivocally determine the role of miR-31 in immune function.  




In this study we present a novel miRNA expression signature in early stages of CD8 T 
cell activation. Our data reveal that CD8 T cells upregulate and downregulate a large number of 
miRNAs early in activation. These data stand in contrast to two previous studies of miRNA 
expression during in vitro differentiation of CD8 T cells into effector memory and central 
memory cells, which reported relatively modest changes in miRNA expression  [142, 143]. Our 
results are consistent with observations in CD4 T cells where large changes in miRNA expression 
early after activation, followed by relatively small differences between memory subsets, were 
observed [37, 49]. There is considerable overlap between the individual miRNAs which are 
reported to be altered in early CD4 T cell activation and our CD8 T cell activation profile, 
including downregulation of miR-181a, miR-150, and the miR-26, miR-29 and miR-30 families, 
as well as upregulation of the miR-17-92 cluster, miR-146, and miR-155. Our data shows 
transient alterations in the expression level of many miRNAs, supporting a significant role for 
miRNA-mediated regulation in early stages of T cell activation.  
We observe strong upregulation of miR-31 in CD8 T cells early after activation, with 
sustained expression in memory T cells. This miR-31induction is calcium responsive and subject 
to inhibition by cyclosporin A. We observed recruitment of NFAT transcription factors to a 
conserved binding site upstream of the miR-31 hairpin upon T cell activation, suggesting that 
NFAT regulates miR-31 expression. However, NFAT transcription factors typically require a 
second transcription factor for optimal DNA binding and transcriptional co-activation. AP1 is the 
classic NFAT partner, but others have been described, including members of the MAF and 
GATA transcription factor families [199]. Additional research is necessary to define the miR-31 
promoter in mice, and closely examine the role of NFAT family members and transcriptional 
partners in regulating pri-miR-31 transcription. 
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 Other groups have observed differential miR-31 expression in T cell subsets. Wu et al. 
reported miR-31 expression in in vitro differentiated CD8 central memory cells. In contrast to our 
results, which indicated that in vitro differentiated effector memory T cells maintained high levels 
of miR-31 expression, Wu et al. failed to detect miR-31 in effector memory T cells, possibly due 
to the technical limitations of the cloning techniques utilized to profile miRNA expression [143]. 
Almanza et al. compared miRNA expression between in vitro differentiated effector memory and 
central memory T cells and observed higher miR-31 expression in effector memory T cells, 
consistent with our data [142]. miR-31 has also been identified as being upregulated in total 
lymphocytes isolated from Il-10 knockout mice, a model for Th1 type autoimmunity, and in 
lymphocytes from mouse models of lupus [200, 201]. It is likely that these results reflect elevated 
miR-31 levels in activated autoimmune T cells.  
A function of miR-31 has been previously investigated in human T cells. Rouas et al. 
have demonstrated that human Treg cells express low levels of miR-31, and demonstrated direct 
repression of the crucial Treg transcription factor Foxp3 by miR-31 [202]. We observed elevated 
miR-31 levels in mouse Treg cells, and the miR-31 binding sites in the human FOXP3 3’UTR are 
poorly conserved in mice [156], suggesting that this role for miR-31 may be specific to human 
Treg cells. While little is known about the role of miR-31 in T cells, there have been a number of 
recent publications on the role of miR-31 in human solid tumors. In this context, miR-31 
expression can function as either an oncogene or a tumor suppressor, depending on cell type. For 
example, miR-31 expression inhibits the proliferation of ovarian carcinomas, but functions as an 
oncogenic miRNA in lung cancer by inhibiting tumor suppressors, including LATS2, which we 
also identify as a target in mouse T cells [171, 172]. The contradictory outcomes of miR-31 
expression illustrate an important aspect of miRNA function: the effects of a miRNA are entirely 
shaped by the mRNA targets expressed in a particular cell type. This is best demonstrated by 
studies on the role of miR-31 on tumor migration and metastasis. In breast cancer and 
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endometrial cancer-associated fibroblasts, miR-31 functions as an inhibitor of metastasis by 
repressing a group of genes, including the homeobox SATB2 and the small GTPase RhoA [203, 
204]. However, in colon carcinoma, miR-31 promotes cell motility by repressing TIAM1, a 
guanidine exchange factor of the Rac GTPase [205]. These data demonstrate the functional 
flexibility of gene regulation by miRNAs and emphasize the need to define the miRNA targets 
for each individual cell type.  
 We identified 11 genes as targets of miR-31-mediated repression in CD8 T cells. Among 
these targets are Lats2, Ppp6c, and Cdkn1a, which have known roles as tumor suppressors, 
supporting our model for miR-31 promotion of activation, proliferation, and survival after T cell 
activation [178, 190, 206].  In addition, published data indicate that Cdkn1a is also regulated by 
the activation-induced miR-17 family [207]. Repression of Cdkn1a by multiple miRNAs may 
play an important role in reversing the quiescent state of naïve T cells and priming cells for rapid 
division.  
In conclusion, we show large alterations in miRNA expression in early stages of CD8 T 
cell activation. We determined the signaling pathways transcriptionally controlling the expression 
of one upregulated miRNA, miR-31, and examined its expression in detail in differentiated T 
cells and other immune cell types. We identified and validated miR-31 targets in primary CD8 T 
cells, including 8 previously unreported target genes. From published information on gene 
function, we propose a model whereby induction of miR-31 primes CD8 T cells for activation by 
repressing pro-apoptotic factors and negative regulators of cyclin, NF-B, and MAPK signaling. 
Increased phosphylation of Erk/MAPK pathway members in mouse T-hybridoma cells after 
ectopic miR-31 transduction supports our model for miR-31-mediated de-repression of T cell 
activation pathways. Our results indicate that miR-31 may play important roles in both early T 
cell activation and long term memory T cell subsets.  
  
















   
86 
 
miRNAs are multipurpose regulators 
One of the most striking aspects of miRNA research is the many phenotypes associated 
with a single miRNA or miRNA family. The potential for repression of many genes through short 
recognition sequences intersects with shifting mRNA transcriptomes to allow a single miRNA to 
play distinct functional roles in different tissue types and developmental stages. In this 
dissertation, we explored miRNA expression and function in three separate but related systems: 
murine hematopoietic development, murine CD8 T cell activation, and human normal B cells and 
CLL cells. While miRNA expression patterns restricted to each system are discussed in detail in 
the relevant chapter, several miRNAs are involved in multiple systems. The most notable of these 
are the miR-181 and miR-29c family, which we identified as differentially expressed during 
hematopoietic development, T cell activation, and in human hematopoietic malignancies.  
miR-181 
The four members of the miR-181 family in mouse and human are derived from 6 
hairpins arranged in 3 separate genomic clusters: miR-181a-1 and miR-181b-1; miR-181a-2 and 
miR-181b-2; and miR-181c and miR-181d. miR-181 was one of the first miRNAs to be 
implicated in hematopoietic development. The first publication from Chen et al. indicated that 
miR-181a was highly expressed in mouse hematopoietic tissues, including bone marrow and 
thymus. Ectopic expression of miR-181a in mouse HSC promoted B cell development and 
impaired CD8 T cell development [36]. These results were confusing, given the strong expression 
of miR-181a observed in the thymus by our group and other researchers. Later research has 
shown that, under the proper developmental conditions miR-181a enhances both T cell and NK 
lineage differentiation [87, 208]. We have demonstrated that commitment to lymphoid lineage 
development correlates with expression of miR-181 family members during murine 
hematopoiesis during both T and B lineage development (Figure 2.1). Given the existing data, the 
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best model for miR-181 function during lineage determination is that it acts to promote general 
lymphoid development, with the specific lymphoid lineage determined by other environmental 
cues. When ectopically expressed in HSC in the bone marrow, an environment suitable for B 
lineage but not T lineage development, miR-181 increases commitment to the B cell lineage. 
When expressed in conditions permissive for T cell or NK cell development, miR-181 assists in 
driving development of these lineages. Little is known regarding the miR-181 target genes 
involved in driving early lymphoid commitment, but a recent report implicated miR-181a 
repression of nemo-like kinase, an inhibitor of Notch signaling, in promotion of NK cell 
differentiation [208]. As Notch signaling is also an essential step in T lineage commitment and 
development, silencing of nemo-like kinase by ectopically expressed miR-181a could also lead to 
the increased T lineage development observed in vitro [87].   
In contrast, the role of miR-181 in modulating late T cell development has been well 
studied. Although miR-181 family expression in DP cells is significantly lower than in DN stages 
of thymocyte development (Figure 2.2B and [79]), it plays an important role in modulating 
positive and negative selection. An elegant paper by Li et al. demonstrated that miR-181a 
repressed a group of inhibitory phosphatases, increasing T cell receptor sensitivity and helping to 
set the threshold for positive and negative selection [79]. Notably, when we examined miR-181 
family expression during SP thymocyte maturation using CD24 expression to separate early SP 
cells, which are still undergoing negative selection, from late SP cells preparing to exit the 
thymus, we observed high levels of miR-181a expression in early SP cells. Late SP cells 
expressed lower miR-181a levels, similar to those observed in mature T cells (Figure 2.2B). This 
expression pattern correlates with continued sensitivity to negative selection in early SP cells. 
Some miR-181 family members are also expressed in mature murine T cells and B cells (Figure 
2.1 and 4.1). Li et al. identified an important role for miR-181a feedback in regulation of the T 
cell response, with stimulation through the TCR downregulating miR-181 expression, leading to 
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lower TCR sensitivity [79]. This data is consistent with our results in mouse T cells and human B 
cells, where we observed miR-181a downregulation in activated mouse T cells and miR-181a and 
miR-181b downregulation in activated human B cells.  
In human malignancies, miR-181 family expression is high in human malignancies 
derived from lymphoid progenitors, and in some myeloid progenitor tumors, but very low in CLL 
(Figures 2.4 and 3.1). This data partially recapitulates developmental-stage specific expression 
that we observe in the mouse. The low expression of miR-181 in CLL is particularly interesting, 
given some intriguing aspects of CLL biology. CLL cells display preferential IgVH usage and 
often express closely homologous CDR3 sequences on both heavy and light BCR chains [209, 
210]. These observations have raised the possibility that stimulation by an auto-antigen may play 
a role in CLL disease. This theory is compatible with our observed miRNA profile, which links 
CLL cells to activated B cells (Figure 3.2). It also offers a potential explanation for the hypo-
responsive BCR response observed in CLL [99]. Chronic antigen signaling in human disease such 
as leprosy has been associated with induction of anergic T cells, an effect which is partially 
mediated by a loss of miR-181a expression [211]. Extending this model to CLL, chronic BCR 
signaling in CLL could lead to the upregulation of miR-155 and downregulation of miR-181a 
observed in CLL, with the loss of miR-181a feedback inducing the hypo-responsive CLL BCR 
response.   
miR-29 
The miR-29 miRNA family is present in two genomic loci in mice and humans, one of 
which contains miR-29b-1 and miR-29a, and a second containing miR-29b-2 and miR-29c. Our 
data and other studies indicate that miR-29 family expression is specifically induced and 
repressed at specific stages of hematopoietic ontogeny. Human and mouse HSC express high 
levels of miR-29a, and miR-29a expression promotes cellular self-renewal [212, 213]. During 
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mouse T cell development we observe low expression of miR-29a and c in thymocytes, and 
significantly higher levels in mature T cells and B cells (Figure 2.1C). Thus, miR-29 family 
expression is lost at some point between HSC and T lineage development in the thymus, and then 
re-induced during T cell maturation. This dynamic expression pattern continues during T and B 
cell activation.CD8 T cell activation leads to downregulation of miR-29a and c (Figure 4.1), and 
this downregulation is linked to enhanced interferon- production [148, 149].Transcription of 
miR-29b-1 and miR-29a has been shown to be repressed by c-Myc, hedgehog, and NF-B 
signaling, consistent with the observed downregulation after T cell activation [214]. Expression 
of miR-29 family members in human B cells was more complex, with miR-29 b and c 
downregulated in response to -BCR or CD40L stimulation, and upregulated in response to TLR 
stimulation. miR-29a displayed the opposite pattern, with upregulation in response to -BCR or 
CD40L, and downregulation in response to TLR ligands (Table 3.1). Profiling of miRNA 
expression in human memory B cell subsets found higher expression of miR-29a, b, and c in 
memory B cells compared to centroblasts[215]. The role of miR-29 family members in B cell 
activation and memory formation is currently unknown.  
The role of miR-29 in cancer is complex and still not fully understood. We observed 
higher expression of all miR-29 family members in CLL vs. normal B cells (Figure 3.1), implying 
that miR-29 expression might play a role in CLL oncogenesis. In support of this possibility, a 
mouse model with conditional overexpression of miR-29a and miR-29b-1 in B cells lead to 
development of a CLL-like disease, and ectopic expression of miR-29a in mouse HSC was 
sufficient to induce AML [212, 216].However, in CLL, our data associated  low miR-29c 
expression with poor clinical markers (ZAP70+ and IgVH unmutated) and shorter time to first 
therapy (Figure 3.4 and Table 3.2). Other published profiles comparing aggressive to indolent 
CLL have also linked low expression of miR-29a, b, and c to an aggressive disease course [217]. 
A potential tumor suppressor role for miR-29 is supported by data indicating miR-29b represses 
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Tcl1, a critical oncogene in aggressive CLL [218]. In addition, low miR-29 family expression has 
been described in multiple other types of cancer, including lung cancer, cholangiocarcinoma , and 
nasopharyngeal carcinomas [114, 219, 220]. Given that the miR-29 family is expressed 
dynamically during hematologic development, it is possible that miR-29 expression in CLL is a 
marker for differentiation stage. The observed association between lower miR-29 and aggressive 
tumors could be due to a connection between low miR-29 expression and less differentiated 
tumors, a hypothesis supported by the association between low miR-29c and IgVH unmutated 
CLL. Future research is necessary to separate correlations betweenmiR-29 and aberrant 
differentiation from the roles of the miR-29 family in oncogenesis or tumor suppression.  
Future research into the role of miRNAs in hematopoietic ontogeny 
Future research on miRNA function during hematopoietic development, the immune 
response, and hematopoietic malignancies will be aided by identification of the signaling 
pathways and transcription factors which regulate pri-miRNA expression. After expression, the 
second important aspect is miRNA target identification and validation. New techniques offer the 
promise of significant improvements in high throughput target identification. The final challenge 
lies in connecting miRNA targets to miRNA dependent phenotypes. 
Determination of miRNA precursors: 
Identification of intergenic pre-miRNA sequences remains a problem for analyzing 
transcriptional control of miRNAs, as we observed for miR-31.We were not able to identify a 
primary transcript for miR-31 through directed approaches, and no potential primary transcript 
has been deposited into GenBank by another group despite miR-31 expression in well studied 
tissues such as mouse kidney and ES cells. Recent technical advances in deep sequencing hold 
promise for identifying miRNAs expressed from the introns of currently unknown transcripts. As 
knowledge of the hematopoietic transcriptome increases, these cryptic transcripts should be 
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revealed. Identification of primary transcripts containing an exonic miRNA could be more 
difficult, given the potential for an exceedingly short half-life for these pri-miRNAs. 
Computational analysis of histone methylation patterns is a promising approach to identifying 
active promoter regions proximal to the miR-31 hairpin [221]. A potential experimental approach 
for isolating exon-encoded pre-miRNA transcripts is conditional knockout of the miRNA 
biogenesis enzyme Drosha. Without Drosha cleavage, these transcripts should be stabilized and 
available for cloning and sequencing. Once the primary transcript has been identified, the same 
techniques developed to analyze protein coding genes can be used to identify miRNA 
transcriptional regulators.  
Isolation of miRNA targets 
It is important to determine miRNA targets in the cell type of interest. At the most basic 
level, the interplay between target and miRNA expression determines miRNA function, as has 
been clearly shown for miR-31 dependent phenotypes in human solid tumors. In addition to gene 
expression, the presence of miRNA target sites can be altered by splicing dependent 3’ exon 
switching and splicing independent use of alternative polyadenylation sites. We observed 
differential miR-31 repression of splice variants from the Ilf3 gene, and detailed microarray 
profile analysis by Sandberg et al. found that both exon switching and use of alternative 
polyadenylation sites is a common feature of T cell activation [144]. These results emphasize the 
need to identify miRNA targets as close to the cell type of interest as possible. Within the 
hematopoietic system, the limited biomass and limited transfectability of most cell types poses 
technical challenges to miRNA target identification.  
Techniques for high-throughput miRNA target identification are typically based on 
miRNA overexpression or knockdown/knockout followed by mRNA expression profiling 
through microarray or deep sequence analysis, biochemical isolation of RISC/miRNA associated 
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mRNA, or proteomic analysis of total protein levels. Of these, mRNA expression profiling 
remains the most commonly used method. In our hands, profiling was an effective means of 
identifying novel miRNA targets. Our data comparing miR-31 to control vector transduced CD8 
T cells found that 57% of downregulated probes were predicted miR-31 targets. This data is 
consistent with ectopic expression of other miRNAs. For example, after ectopic expression of 
miR-124 in Hela cells, 65% of downregulated mRNAs contained a 7-mer match to the seed 
region of miR-124 [222]. However, this effect is not observed in all systems. Boldin et al. did not 
observe significant upregulation of predicted miR-146a targets in miR-146a knockout 
macrophages, even for targets shown to be regulated at the protein level [50]. The relatively 
modest target downregulation induced by miRNA binding makes detection difficult, and some 
targets may be regulated exclusively at the level of translation. Thus, expression profiling may 
not be sufficient to identify all targets.  
Alternative techniques for detection of miRNA targets are in development. Stable isotope 
labeling of cultured cells followed by detection by mass spectrometry can detect downregualtion 
of miRNA targets at the protein level [167, 168]. This technique has provided essential 
information regarding the correlation between changes in protein level and mRNA levels in 
miRNA repressed mRNAs, but the expense, technical difficulty, and high biomass required 
currently renders it infeasible for most miRNA studies. A second approach is to identify miRNA 
or RISC bound mRNAs. Co-purification of mRNAs bound to RISC has a proven record in 
identifying true miRNA targets [223, 224]. The primary problem with this technique is that it 
enriches for all RISC-associated mRNAs, making identification of the targets of a particular 
miRNA difficult. A recently developed extension of this technique known as Ago HITS-CLIP 
(high throughput sequencing by cross-linking and immune-precipitation) partially addresses this 
problem [225].This method involves Ago precipitation followed by digestion of unprotected 
RNA, sequencing of Ago protected fragments, and analysis of predicted binding sites within the 
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protected sequence. This method is a dramatic improvement in specificity, although Ago 
protected fragments are 40-60 nt long, and can contain multiple miRNA binding sites. While 
promising, attempts to identify targets of a specific miRNA by directly precipitating mRNAs 
bound to a labeled miRNA have met with limited success [226, 227]. These improvements in 
miRNA target algorithms both aid in identifying miRNA targets, and also hold the potential to 
further elucidate the currently unknown factors which separate functional miRNA target sites 
from similar non-target sequences.  
Correlating miRNA expression, miRNA targets, and miRNA dependent phenotypes 
The most common technique for connecting miRNA targets to a miRNA dependent 
phenotype involves repressing the level of individual targets with siRNAs, or ectopically 
expressing miRNA-insensitive target variants. For example, were able to partially phenocopy the 
pro-activation effect of miR-31 in T-hybridoma cells by silencing the Lats2 or Ppp6c target genes 
(Figure 4.6), and the increase in NK cell development due to miR-181a can be phenocopied by 
silencing of nemo-like kinase [208]. For miRNAs with a known phenotype which is amenable to 
high throughput screening, siRNA screens can be used to isolate phenotype-associated genes, 
offering a subset of potential miRNA targets which are already linked to a phenotype. A recent 
paper on the role of miR-19 in T-ALL identified 4 novel miR-19 target genes among the set of 8 
target genes where siRNA silencing phenocopied miR-19 expression [228]. However, many 
miRNA dependent phenotypes depend on concurrent low level repression of many individual 
genes, and cannot be duplicated by altering the expression of a single target. Silencing of 
individual target genes was not able to recapitulate the effect of miR-181a on TCR sensitivity 
[79], and phenocopy of the anti-metastatic effect of miR-31 in breast cancer required silencing of 
3 target genes [229]. Where the roles of target genes are well understood, computational analysis 
of gene networks can aid in isolating critical target genes [230]. Experimental identification of 
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genes responsible for multi-gene phenotypes could be accomplished by screening with Pol-II 
based multi-siRNA libraries containing random combinations of predicted targets, or through the 
expression of multiple target protectors, which compete for miRNA binding to individual target 
genes [231, 232]. Despite technical advances, tracing the connection between miRNAs, their 
target genes, and miRNA dependent phenotypes will remain the primary challenge in miRNA 
research.  
Conclusions 
In this dissertation, we present data on miRNA expression in three systems: murine 
hematopoietic development, murine CD8 T cell activation, and human normal B cells and CLL 
cells. In each system, we have investigated a subset of miRNAs in detail. In murine 
hematopoiesis, we observed that 2 microRNA families, miR-181 and miR-128 were expressed in 
thymocytes. We demonstrated that these miRNA families are induced during commitment to 
lymphoid lineage and that expression is maintained throughout T cell development in the thymus 
and B cell development in the bone marrow. In human B cells and CLL, we identified common 
miRNA expression signatures in CLL and B cell activation, as well as miRNAs which correlate 
with CLL clinical markers and disease progression. In murine CD8 T cells, we identified a novel 
profile for miRNA expression during CD8 T cell activation, and investigated the function of one 
little-known activation induced miRNA, miR-31 in detail. We determined miR-31 expression 
patterns in CD4 and CD8 T cell subsets, and show that miR-31 induction during T cell activation 
is regulated by signaling through calcium and calcineurin. We identified miR-31 targets in 
primary CD8 T cells, a subset of which were previously identified in human solid tumors.  Based 
on these targets, we hypothesize that miR-31 expression promotes T cell survival, activation, and 
proliferation.  
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